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ABSTRACT
SALVIANOLIC ACID B FOR PULMONARY DELIVERY TOWARDS REVERSAL
OF EMPHYSEMA
by Sneha Dhapare, M.S., B.Pharm.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Major Director: Masahiro Sakagami, Ph.D.
Associate Professor
Department of Pharmaceutics, School of Pharmacy
A new pathobiologic hypothesis has recently emerged that the alveolar structural
destruction and loss in emphysema are caused by the deficiency of vascular endothelial
growth factor (VEGF). Therefore, this project hypothesized that such pathobiologic VEGF
deficiency of emphysematous lungs can be recovered with a natural caffeic acid tetramer,
salvianolic acid B (SalB), through activation of signal transducer and activator of
transcription 3 (STAT3), so that emphysema can be reversed as a result of inhibition of
induced cell death, stimulation of cell proliferation and migration, and promotion of stem
cell recruitment to the lungs.
SalB was first shown to be potently anti-oxidative (IC50 = 3.7 µM), but devoid of
anti-elastase activity. SalB was then administered to the lungs of healthy rats at 0.2 mg/kg
for two weeks, verifying ~1.7-fold increased lung tissue expressions of phosphorylated
STAT3 (pSTAT3; an activated form of STAT3) and VEGF. Subsequently, SalB was
examined in the anti-cell death assay, cell proliferation and migration assays, and trans-

xviii

endothelial stem cell recruitment assay in the in vitro lung epithelial (A549) and
endothelial (HMVEC-L) cell systems. SalB at 25 µM exerted significant 48-88 %
inhibitory activities against cell death induced with oxidative stress and VEGF receptor
blockade (with SU5416) in both cell systems, measured by the trypan blue exclusion and
propidium iodide-based flow cytometry assays. SalB at 25 µM also stimulated A549 and
HMVEC-L cell proliferation by ~1.4-fold and promoted cell migration by ~1.6-fold, while
recovering stem cell recruitment impaired with SU5416 by 60 %. The anti-cell death, and
proliferation and migration stimulatory activities of SalB were significantly opposed by
pharmacological inhibitors of JAK2 (Janus kinase 2; an upper signal of STAT3), STAT3
and VEGF.
SalB was then examined for its in vivo reversal activities in emphysema induced
with porcine pancreatic elastase (PPE) and cigarette smoke extract (CSE) in rats. Upon
establishment of emphysema on day 21, SalB was administered to the lungs three times
weekly over three weeks. SalB at 0.2 mg/kg significantly recovered ~85 %-impaired
treadmill exercise endurance by 57-82 %; and reduced abnormal airspace enlargement by
59-75 %. In the PPE-induced emphysematous rats, SalB also reduced the 4-fold greater
alveolar destruction index by 61 %. The lung tissue protein expression by Western blot
analysis found that cleaved caspase 3 (cell apoptotic marker) was induced by 13-fold, and
VEGF was reduced by 60 % in the PPE -induced emphysematous rats. However,
pulmonary treatment with SalB at 0.2 mg/kg normalized these proteins, and also
significantly increased the expression of a cell proliferation marker, proliferative cell
nuclear antigen (PCNA) by 2.6-fold. Note however that SalB treatment did not reduce the
neutrophilic myeloperoxidase activity in the lungs induced in the PPE-induced rats. Taken

xix

all together, this study has demonstrated that SalB potently inhibited lung cell death,
stimulates lung cell proliferation and migration, and restores stem cell migration with its
mechanism of STAT3 activation and VEGF elevation and reversed established
emphysema in rat models.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE

1.1. COPD and Emphysema
Chronic obstructive pulmonary disease (COPD) is comprised of two lung
diseases, chronic bronchitis and emphysema (Rabe et al. 2007). Hence, emphysema is a
manifestation of COPD, and pathobiologically causes a loss of lung's elastic recoil and
destruction of the alveolar septa, resulting in airspace enlargement and airflow
obstruction (Snider et al. 1985). This alveolar structural destruction and loss are
progressive and believed to be irreversible, thereby eventually leading to death (Snider et
al. 1985). Epidemiological studies indicate that COPD affects 24 million Americans, but
a half of them remain undiagnosed (Akinbami et al. 2013). It is currently the thirdleading cause of death in the United States (US) with annual 120,000 deaths, and is
predicted to be the third-leading cause of death worldwide by 2020 (Punturieri et al.
2008). In the US, its increasing socioeconomic burden reaches $50 billion in annual
direct and indirect health care expenditures (Akinbami et al. 2013). Even so, the
pharmacological treatment of COPD/emphysema remains palliative only to improve the
disease status (Diette et al. 2015). While chronic cigarette smoking is the predominant
risk factor, COPD/emphysema also occurs in non-smokers, 35 % of which are due to
genetic factors like the α1-antitrypsin deficiency or air pollution in low-to-middle income
countries (WHO 2004).
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1.2. Current Treatment of COPD/Emphysema
Approximately 85 % of COPD/emphysema deaths are associated with active or
passive exposure to cigarette smoke (Marcelino et al. 2014). Hence, smoking cessation is
a preventive therapy, yet it has shown a very low success rate of 7-10 % (Messer et al.
2008). This is in contrast to the nicotine replacement therapies using nicotine gum,
patches, lozenges, nasal spray, and inhalers, reporting an increased success rate of
smoking cessation by 60 % (Zhang et al. 2015). In fact, a Cochrane systematic review has
attested that a combination of behavioral treatment and pharmacotherapy is the most
effective in helping smokers with COPD quit smoking (van Eerd et al. 2016). Meanwhile,
pulmonary rehabilitation programs like lung volume reduction surgery (LVRS) have
resulted in improved performance in some patients with severe emphysema, however,
they are cost-prohibitive and are associated with an increased risk of morbidity and
mortality (van Agteren et al. 2006). The current inability in transforming
COPD/emphysema treatment has been suggested to be associated with a number of
factors including failure to diagnose early stages of the disease (Marchetti & Criner
2016).
To date, the pharmacological treatment options for COPD/emphysema are limited
to inhaled corticosteroids (ICSs), bronchodilators (β2 agonists and anticholinergic) and
phosphodiesterase-4 inhibitors or a combination thereof (Stockley et al. 2008). Table 1
summarizes the commonly used medications in COPD/emphysema approved by the US
Food and Drug Administration (FDA) (Schamberger et al. 2014). These are used to
manage symptoms, reduce the frequency and severity of exacerbations and improve the
overall health by treating the co-morbidities (Punturieri et al. 2008; Marchetti & Criner
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2016). Nevertheless, none of these molecules have conclusively shown to modify the
long-term lung function decline seen in COPD/emphysema patients (GOLD 2017; Barnes
& Stockley 2005). Therefore, there is no pharmacological therapy to reverse or repair
emphysematous lung damages (Marchetti & Criner 2016). New molecules for COPD that
are currently being studied in clinical trials include anti-inflammatory agents:
theophylline, phosphoinositide 3-kinase inhibitors and curcumin; and anti-oxidants:
andrographolide, sulforaphane and chalcones (https://clinicaltrials.gov). However, again,
these molecules are expected for management of the disease symptoms, so that reversal
of the emphysematous lung damages would not be feasible.

4

Table 1.1: FDA approved drugs for COPD/emphysema treatment (Schamberger et
al. 2014)

5

1.3. Pathogenesis of COPD/Emphysema
While chronic cigarette smoking has been shown to be the most important risk
factor in COPD/emphysema, its pathogenesis still remains enigmatic even as of today
(Taraseviciene-stewart & Voelkel 2008; Fletcher & Peto 1977). Cigarette smoke has
protean detrimental effects on both the lung’s epithelia and endothelia, causes damages
and loss of the microvasculature, and eventually destroys alveolar structures (Figure 1.1)
(Hueper et al. 2015). It has been a long-term belief that this is due to three predominant
pathogenic factors, namely, oxidative stress, elastolysis and inflammation, collectively
referred to as the “triple threat” (Snider 1981). Accordingly, potential applications of
inhibitors of each of these pathways have been explored over the last three decades, but
remain to prove beneficial in reversing emphysema in clinical studies (Fischer et al.
2011).
The alveolar septa in patients with COPD are thin and often almost avascular,
which implies that reduced vascularization may be involved in this pathogenesis (Liebow
1959). Although the “triple threat” hypothesis is supported by the evidence of elevated
lung inflammation, oxidative stress and proteolysis in emphysema, it does not explain
how the progressive nature of the alveolar structural destruction and loss persists even
after cessation of smoking (Fletcher & Peto 1977). As a part of the effort to clarify if
alternate cellular mechanisms are responsible for the development and progression of
emphysema, Kasahara et al. (2000) identified that endothelial cell apoptosis was induced
in emphysema lungs, associated with reduced expression of vascular endothelial growth
factor (VEGF) and one of its receptor, VEGF -receptor 2 (VEGFR2). Accordingly,
Kasahara et al. (2001) then showed that the blockade of VEGF -receptor induced
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endothelial cell death by apoptosis and emphysema in rats. Reduced VEGF expression in
the sputum and lung tissues of emphysema patients were also identified, which supported
the impaired VEGF signaling in emphysema (Kanazawa et al. 2003; Yasuo et al. 2011).
Subsequently, this “VEGF deficiency” was linked to decreased expressions of VEGF’s
upstream regulating molecules, hypoxia inducible factor 1 α (HIF-1α) and histone
deacetylase (HDAC), seen as a result of chronic cigarette smoking (Ito et al. 2005;
Mizuno et al. 2011). These evidences were sufficient to propose VEGF as a critical “lung
structure maintenance factor” and thus, its reduced expression and impaired signaling as
an essential pathologic mechanism in emphysema lungs (Medford & Millar 2006). If so,
pharmacological recovery of VEGF expression may be an approach for lung structural
repair and reversal of emphysema.
VEGF and its signaling are however involved in many aspects of COPD, more
than just emphysema, such as bronchial wall remodeling and pulmonary hypertension.
Thus targeting VEGF in COPD may cause off-target effects on some of such other
aspects, which are largely unknown or unpredictable (Bakakos et al. 2015). Even so, the
loss of alveolar capillary structure in emphysema surely causes a vascular disease, which
can be corrected by restoring and/or stimulating VEGF expression, given the
vulnerability of the endothelial cells to VEGF paracrine and autocrine survival signals
(Taraseviciene-stewart & Voelkel 2008). Apart from improving cell survival, VEGF is
also proposed to promote repair of the adult lung tissues in emphysema, given its role as
an important growth factor.
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Figure 1.1: Normal and emphysematous alveoli in the lung (Taraseviciene-Stewart & Voelkel
2008)
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1.4. JAK2-STAT3-VEGF Signaling Pathway
One of the upstream regulators for both VEGF and HIF-1α is the signal
transducer and activator of transcription 3, STAT3 (Xu et al. 2005). Upon activation of
cytokine, erythropoietin or growth factor receptors bound to intracellular janus kinases 2
(JAK2), STAT3 is phosphorylated to its active form phosphorylated STAT3 (pSTAT3),
which induces its dimerization and translocation into the nucleus for binding to the
VEGF promoter region for VEGF transcription, as schematically described in Figure 1.2
(Chen & Zhong 2008; Dong et al. 2010). This pSTAT3 is also associated co-operatively
with HIF-1α on the VEGF promoter region to participate in VEGF regulation (Xu et al.
2005). Therefore, activation of the JAK2-STAT3 signaling can in theory elevate tissue
expression of VEGF.
Apart from its critical role in VEGF regulation, STAT3 is also a key factor to
promote cell proliferation, differentiation and angiogenesis (Chen & Zhong 2008).
Cigarette smoke was shown to induce STAT3 activation, playing a protective role in
maintaining normal lung homeostasis and function by regulating critical processes in
inflammation, apoptosis, and protease expression (Geraghty et al. 2013). This study
speculated that targeting STAT3 could be used as an approach to counter the injurious
effects of cigarette smoke exposure. JAK2 has also been shown to play an important role
in mediating proliferation and differentiation of alveolar cells (Wagner et al. 2004). Thus,
targeting JAK2-STAT3 could correct pathologically reduced VEGF levels in emphysema
to promote lung repair by increasing cell survival and proliferation.
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Figure 1.2: Intracellular JAK2-STAT3-VEGF activation pathway
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1.5. Salvianolic acid B (SalB)
SalB is a polyphenol and a major water-soluble bioactive compound extracted
from danshen, a dried root of Salvia militiorrhiza (Figure 1.3). As a traditional Chinese
medicine, danshen has long been used to improve blood circulation in the treatment of
cardiovascular diseases. Hence, many danshen products are commercially available as
oral tablets, capsules, liquids and dripping pills as well as for intravenous injection,
creating a $120 million market worldwide (Chen et al. 2014). However, danshen has not
yet been approved by the FDA and is currently in Phase II clinical trials for
cardiovascular disease treatments (https://clinicaltrials.gov).
SalB has been studied in animal models for anti-oxidation, anti-inflammation,
anti-coagulant, anti-thrombotic, anti-cancer and angiogenic activities (Wang et al. 2013).
These activities were aimed at treating diseases like myocardial infarction, ischemiareperfusion injury, atherosclerosis, Alzheimer disease and head and neck cancer (Ho &
Hong 2011; Zhao et al. 2011; Chen et al. 2014; Lay et al. 2003). The applications of
SalB, however, have been limited due to its poor oral bioavailability of less than 3% (Wu
et al. 2006). Moreover, despite such various activities, its cellular and molecular targets
or downstream signal network has not been clarified (Feng et al. 2011).
SalB was shown to increase angiogenesis by enhancing the gene expression of
VEGF and its receptor in murine endothelial cells (Lay et al. 2003). Another recent study
reported an increased expression of pSTAT3 following SalB treatment in embryonic stem
cells (Liu et al. 2014). Hence, these SalB’s promotion of STAT3-VEGF signaling may be
capable of pharmacologically reversing the reduced VEGF expression in emphysematous
lungs. In addition, its anti-oxidative and anti-inflammatory properties may also suppress
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the induced oxidative stress and inflammation. Given its low oral absorption,
hydrophilicity and ionization potential, SalB when administered via inhalation, is
expected to result in slower and lower absorption from the lung and thereby in turn
enable longer retention. It was hypothesized therefore that pulmonary administration of
SalB is capable of STAT3 activation and VEGF elevation, thereby reversing lung
damages in emphysema, as shown in the Figure 1.4.
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A)

B)

Salvianolic acid B
Molecular formula: C36H30O16
Molecular weight: 718.61
LogP = 2.14 (Huang et al. 2014)
LogD7.5 = −2.88 (Zhou et al. 2009)
pKa = 2.77 (Huang et al. 2014)

Figure 1.3: (A) Salvia militiorrhiza; and (B) the structure and physicochemical properties of
its major active component, salvianolic acid B (SalB) (Wang et al. 2013).

13

Figure 1.4: Proposed mechanism for emphysema reversal by SalB
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1.6. Towards Reversal of Emphysema
Alveolar structural destruction and loss in emphysema are considered to be the
result of a pathologic imbalance between cell death and cellular repair processes, and has
been attributed, at least in part, to the VEGF deficiency (Lee et al. 2012; Morissette et al.
2009). VEGF receptor blockade in animals induced apoptosis of lung cells and caused
emphysema that remained irreversible even by their natural repair mechanisms (Kasahara
et al. 2001; Voelkel et al. 2006). Correcting this progressive cell loss would be critical in
restoring the alveolar structures. While deficiency of growth factors like VEGF was
linked to reduced cell proliferation, conflicting evidences exist as to cell proliferative
activities in emphysematous lung (Yokohori et al. 2004; Imai et al. 2005). Regardless of
the disease state, however, stimulating cell proliferation would be essential to restore the
alveolar structure and function. Emphysema has also been characterized by dysregulated
wound healing and cell migration processes, which is also somehow regulated by VEGF
(Shaw & Martin 2016; Perotin et al. 2014). Thus restoring VEGF can be proposed not
only to protect the lung cells from damages, but also to promote cell proliferation and
migration towards reversal of emphysema.
A modern concept has emerged that both tissue resident and bone marrow–
derived circulating stem cells participate in the (patho)physiologic maintenance of the
adult lung structures (Taraseviciene-stewart & Voelkel 2008). Among such stem cell
populations, mesenchymal stem cells (MSCs), progenitor cells of mesodermal origin,
have shown the most promising results in many cases owing to their multi-lineage
potential and ability to migrate to the sites of tissue injury and to exert anti-inflammatory
activities (Siniscalco et al. 2008). However, homing to the lung in the recruitment of such
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bone marrow-derived stem cells is considerably inefficient (Conese et al. 2014).
Moreover, as VEGF regulates stem cell mobilization and recruitment, it has been
speculated that these processes may be impaired in emphysema (Ishizawa et al. 2004;
Taraseviciene-stewart & Voelkel 2008). If so, a molecule intended to repair damaged
lungs in emphysema can also promote recruitment of circulating stem cells into the lung.
The complementary processes of cell death and cell proliferation, migration and
recruitment may therefore need to be balanced in emphysema, as shown in Figure 1.4.
While the VEGF hypothesis naturally concerns endothelial cell death (Kasahara et
al. 2000), the proteases and oxidants imbalance hypotheses (Morissette et al. 2011)
concern epithelial cell damages in emphysematous lung. However, studies have shown
that there are significant interactions between the two cell types in the alveoli, such that a
severe damage to one could lead to disruption of the other (Sirianni et al. 2003). Thus,
both of these cell types are necessary to study, when emphysema reversal activities are
sought. Moreover, damages to the alveolar type I (ATI) cells stimulate proliferation and
migration, and even differentiation of surviving alveolar type II (ATII) cells at the
wounded sites (Kim et al. 2010; Sugahara et al. 2006).
Taken all together, this dissertation project aimed to demonstrate the reversal
activities of SalB as a novel natural chemical entity for pulmonary delivery in the
treatment of emphysema and COPD. After confirming its anti-oxidative activity and lack
of anti-elastase activity, a series of in vitro lung epithelial and endothelial cell systems
were used to examine its inhibitory activities in cell death; and promoting activities of
cell proliferation, migration and trans-endothelial migratory recruitment of MSCs. Their
JAK2-STAT3-VEGF dependence was also examined with respective pharmacologic
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inhibitors. SalB was examined with pulmonary delivery in the rat models of established
emphysema induced with porcine pancreatic elastase (PPE) and cigarette smoke extract
(CSE). The lung functional and morphological recoveries as well as changes of key
protein and biochemical markers in the lungs were determined.
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CHAPTER 2
HYPOTHESES AND SPECIFIC AIMS

This dissertation project aimed to demonstrate the therapeutic activity of
salvianolic acid B (SalB) as a novel drug molecule for pulmonary delivery in the
treatment of emphysema. It was hypothesized that SalB reverses established emphysema
by pharmacologically recovering and/or stimulating VEGF expression in the lungs
through STAT3 activation. Specifically, this project was designed and structured 1) to
confirm the anti-oxidative activity, absence of anti-elastase activity, and lung’s STAT3
and VEGF elevating activity of SalB 2) to examine JAK2-STAT3-VEGF dependent anticell death, cell proliferation, migration and MSC recruitment promoting activities of SalB
in a series of in vitro cell systems; and 3) to assess the reversal activities of SalB in the in
vivo rat models of established emphysema. This project pursued the following 5
hypotheses:
1. SalB is potently anti-oxidative but not anti-elastase, while elevating the lung tissue
expression of STAT3 and VEGF following pulmonary administration
2. SalB exerts potent JAK2-STAT3-dependent anti-cell death activities against lung
epithelial and endothelial cell death induced with oxidative stress and by VEGF
receptor blockade
3. SalB exerts potent JAK2-STAT3-VEGF-dependent lung epithelial and endothelial
cell proliferation and migration stimulatory activities
18

4. SalB promotes the trans-endothelial migratory recruitment of stem cells
5.

Pulmonary administration of SalB enables functional and morphological reversal of
emphysema induced with porcine pancreatic elastase (PPE) and cigarette smoke
extract (CSE) in rats by normalizing VEGF expression

In Chapter 3, SalB will be examined in the in vitro systems to confirm its antioxidative potency and lack of anti-elastase activity. Additionally, SalB’s in vivo
potencies for STAT3 activation and VEGF elevation will be identified in healthy rats
following pulmonary administration. In Chapter 4, SalB’s inhibitory activities against
induced emphysematous cell death and stimulatory activities in cell proliferation and
migration will be assessed in the lung epithelial and endothelial cell systems. The effects
of JAK2, STAT3 and VEGF inhibitors on each of these activities will also be assessed to
explore its mechanism of action. Subsequently, the in vitro trans-endothelial migration
assay for MSCs will be developed and used to assess SalB’s promoting activities of MSC
migratory recruitment with or without VEGF receptor blockade. In Chapter 5,
emphysema will be induced and established with PPE and CSE and then, SalB will be
administered to the lungs over 3 weeks. Changes in the lung functionality and
morphology as well as key protein and biochemical markers in the lungs will be
determined. Finally, Chapter 6 will summarize all the findings in this dissertation project
and provide overall conclusions.
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CHAPTER 3
SALVIANOLIC ACID B (SalB): ANTI-OXIDATIVE, ANTI-ELASTASE AND
STAT3 AND VEGF ELEVATING ACTIVITIES

3.1. Introduction
As described in Chapter 1, anti-oxidative and anti-elastase activities continue to
be sought to treat damaged lungs of emphysema and COPD, given their “triple threat”
pathogeneses of induced oxidative stress, elastolysis and inflammation (Snider 1981). By
contrast, “VEGF deficiency” has also been implicated in the emphysematous lungs as a
result of impaired epigenetic regulations (Yasuo et al. 2011; Wagner 2003). In this
context, a naural polyphenolic caffeic acid tetramer, salvianolic acid B (SalB), has
become of our interest as a molecule that may be capable of treating damaged lungs in
emphysema by virtue of its catechol-based anti-oxidative activity as well as its potency of
stimulating VEGF signaling via activation of an upstream transcription factor STAT3
(Zhao et al. 2008; Liu et al. 2014). However, whether SalB posesses anti-elastase activity
in addition to the anti-oxidative activity, activates STAT3 and elevates VEGF in lung
tissues remain unknown. Hence, in this chapter, SalB was examined in the in vitro
chromogenic radical scavening and elastase inhibitory activity assays. SalB was also
assessed in vivo in rat lungs to examine its potency and effective dose to activate STAT3
(i.e., STAT3 phosphorylation) and elevate VEGF as a molecular proof of concept for the
assessments of in vitro and in vivo therapeutic activities in emphysma in Chapter 4 and 5.
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3.2. Materials and Methods
3.2.1. Anti-oxidative activity assessment
SalB was purchased from Ivy Fine Chemicals (98 % purity, Cherry Hill, NJ) as a
pale yellow-to-off white powder and stored at room temperature in a desiccator with
silica gel prior to experiments. The in vitro chemical anti-oxidation assay kit obtained
from Cayman Chemical Company (Ann Arbor, MI) was used in a 96-well plate format,
according to Cayman’s protocol. The assay employed formation of a stable chromogenic
+

radical cation, ABTS

from 2,2'-azinobis(3-ethyl-benzothiazoline-6-sulphonic acid)

(ABTS) during incubation with metmyoglobin and hydrogen peroxide (H2O2) at room
temperature. This produced a blue-green color that could be measured at 750 nm. SalB
was added at 0.01-100 µM in this assay kit, and the absorbance change (ΔAbs) in the first
5 min was monitored using a plate reader (SynergyTM 2, BioTek Instruments, Inc.,
+

Winooski, VT) as the initial rate of ABTS production. The ΔAbs (Y) was then plotted
as a function of logarithmic concentrations (C) of SalB. The half-maximal (50 %)
inhibitory concentration (IC50) and Hill slope (HS) values were derived from the
concentration-response curves fitted to the following 4-parameter logistic function
equation:

Y= Ymin + (Y0-Ymin) / [1+(C/IC50)HS]

Where, Y0 is the ΔAbs value in the absence of SalB and Ymin is the lowest asymptotic
ΔAbs value seen at the highest test concentration (i.e., 100 µM). The non-linear curve
fitting was performed using Prism® 7 (GraphPad Software, San Diego, CA). The
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“goodness-of-fit” of the curve fitting was ensured with >0.99 of the Prism-derived R2
values, in addition to visual inspection of residuals.

3.2.2. Anti-elastase activity assessment
The in vitro anti-elastase activities of SalB were determined using human sputum
elastase (HSE) hydrolysis of a chromogenic substrate N-methoxysuccinyl Ala-Ala-ProVal p-nitroanilide (MeOSuc-AAPV-pNA, Sigma-Aldrich) in a 96-well format, according
to the method described by Saluja et al. (2013). MeOSuc-AAPV-pNA was prepared as a
8.75 mM stock solution in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO).
HSE (8750 U/mg) purchased from Elastin Products and Co. (Owensville, MO) was
prepared as a 50 U/ml stock solution in acetate buffer (pH 5.5). A 0.18 ml solution of
SalB at 0.1 – 200 µM was incubated with 0.02 ml of HSE stock solution and 0.06 ml of
the 0.87 mM MeOSuc-AAPV-pNA solution to initiate the hydrolysis reaction. The initial
rate of absorbance change (ΔAbs) due to p-nitroaniline generation was measured in the
first 10 min at 405 nm using the microplate reader (SynergyTM2). The fraction of HSE
activity remaining (Y) was determined from the following equation and plotted as a
function of logarithmic concentration (C) of SalB:
!"#$%!"# !" !"# !"#$%$#& !"#$%&%&' =

∆!"# !"#ℎ !"#$
∆!"# !"#ℎ!"# !"#$

The IC50 and HS values were derived from the concentration-response curves fitted to the
4-parameter logistic function equation, as described above (3.2.1. Anti-oxidative activity
assessment).
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3.2.3. In vivo pSTAT3 and VEGF activation in the lung tissues
Adult male Sprague-Dawley rats (250–275 g; Hilltop Lab Animals, Scottdale,
PA) were used, according to the animal experimental protocols approved by the VCU’s
Institutional Animal Care and Use Committee (IACUC). Saline or SalB at 0.2 mg/kg (0.1
ml) was orotracheally spray-instilled to the lung with PennCentury’s Microsprayer under
short anesthesia with isoflurane once daily for 5 days per week over two weeks, as
described previously (Saluja 2014). Animals were then sacrificed via exsanguination
under surgical anesthesia with an intraperitoneal urethane at 1 g/kg. While the left lung
lobes were inflated with warm agarose solution (0.5 %) for the assessment of the airspace
enlargement (as described in Chapter 5), the right lung tissues were immediately minced
for Western blot analysis to determine the lung tissue levels of pSTAT3 and VEGF, as
described below.
Western blot analysis is fully described in the Appendix 1. The minced lung
tissues (300 mg) were homogenized on ice using hand homogenizer (Pro 200; Pro
Scientific, Inc., Oxford, CT) with the NP-40 lysis buffer. The lysis buffer was 1 %
Nonidet P40 (NP-40; Thermo Fisher Scientific, Waltham, MA), 50 mM Tris (pH 8;
Sigma-Aldrich) and 150 mM NaCl (Thermo Fisher Scientific), which dissolved a
cOmpleteTM protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN),
according to the supplier’s recommendation. For detection of pSTAT3, a PhosSTOPTM
phosphatase inhibitor tablet (Roche) was also dissolved in the lysis buffer, according to
Roche’s recommendation. Supernatant was collected after centrifugation at 16,000 g in
4˚C (Aventi JE Centrifuge; Beckman Coulter).
After protein content determination by the BCA assay (Thermo, Grand Island,
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NY), 40 µg of protein was denatured at 100 ˚C for 10 min, electrophoresed on a 10 %
Mini-PROTEAN TGX polyacrylamide gel (Bio-Rad; Hercules, CA), and transferred to
the nitrocellulose membranes (0.2 mm; Bio-Rad). After 1 h blocking at room temperature
in the blocking buffer recommended for each antibody by its supplier, the membrane was
probed via overnight incubation at 4 ˚C with each of the mouse or rabbit antibodies raised
against: pSTAT3 (1:1000, phosphorylated STAT3-Tyr705, rabbit polyclonal, #9131, Cell
Signaling Technology, Danvers, MA), VEGF (1:100, mouse monoclonal, sc-7269, Santa
Cruz, Dallas, TX) and ß-actin (1:5,000, mouse monoclonal, Sigma-Aldrich). The
membranes were then incubated in horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit antibody (Bio-Rad Laboratories) for 80 min at room temperature. The probed
protein was detected with the SuperSignal West Pico enhanced chemiluminescent
substrate kit (Pierce, Rockford, IL) in the film processor (X-Omat 2000A; Eastman
Kodak, Rochester, NY). Their band signals were quantified with the ImageJ software
(NIH, Bethesda, MD). Each protein signal was normalized with the corresponding ß-actin
signal within the same membranes, and expressed as the value relative to that for the
untreated healthy rat lungs.
3.2.5. Data description and statistical analyses
The results of the in vitro anti-oxidative and anti-elastase assessments were
expressed as mean ± standard deviation (SD) from triplicate experiments (n=3). The in
vivo protein expression results were expressed as treatment group mean ± standard error
(SE) from n = 3 or 4. Statistical analyses for group comparison were performed with
JMP-Pro® 12 (SAS Institute, Inc., Cary, NC) using two-tailed t-test with p<0.05 as
significant.
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3.3. Results and Discussion
3.3.1. In vitro ABTS radical scavenging activity of SalB
+

Figure 3.1 shows the ΔAbs in the first 5 min due to ABTS generation at various
concentrations of SalB. SalB exhibited potent concentration-dependent radical
scavenging activities, as indicated by ΔAbs suppression with increasing concentration.
The IC50 value was 3.67±0.09 µM (95% CI: 3.48-3.88 µM). This ABTS scavenging
activity was more potent than the same radical scavenging activity of Trolox (IC50 = 9.4
µM) as well as caffeic acid (CA) 16.82±1.16 µM (Saluja et al. 2013). Due to its
polyphenolic nature, SalB has been thought to possess antioxidant activity. In fact, the
-

reactive oxygen species (ROS) scavenging activity of SalB against HO, O2 , DPPH
(2,2-diphenyl-1-picryl-hydrazyl-hydrate) radicals was found to be more potent than that
of Vitamin C (Zhao et al. 2008). Since SalB is structurally a CA tetramer, the 4 -fold
more potent activity of SalB is likely related to this oligomer structure. The catechol
moiety in the structure of SalB and CA has also been shown to exert the anti-oxidant
property (Rice-Evans, 1996). The anti-oxidative effects of SalB and CA may therefore be
attributed to this catechol moiety that has also been found in other CA oligomers (Saluja
et al. 2013). The Hill-slope value for SalB was 3.7±0.3, which suggested apparent cooperativity. By the virtue of this anti-oxidative activity, SalB was further examined in
Chapter 4 to assess its cytoprotective activity against oxidative stress-induced cell death.
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Figure 3.1: The absorbance increase in 5 min (∆Abs) at 750 nm as a function of concentration
of SalB in the chemical antioxidant assay. Data: mean±SD (n=3). The solid lines are the result
of curve-fitting.
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3.3.2. In vitro anti-elastase activity of SalB
The in vitro elastase inhibitory activity of SalB was assessed using the substrate
hydrolysis assay that utilized a chromogenic HSE substrate to release p-nitroaniline,
detected at 450 nm (Bieth & Wermuth 1973). Figure 3.2 shows the fraction of HSE
activity remaining in the presence of different concentrations of SalB. SalB was devoid of
HSE inhibitory activity at least upto 0.2 mM. This lack of HSE inhibitory activity of SalB
implied a lack of elastolytic inhibition in the rat model of emphysema used to examine
the reversal activity of SalB described in Chapter 5.
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Figure 3.2: The fraction of HSE activity remaining as a function of concentration of SalB in the
chromogenic substrate hydrolysis assay. Data: mean±SD (n=3).
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3.3.3. Elevated pSTAT3 and VEGF expression in the lungs following SalB treatment
Figure 3.3 (A) shows the representative Western blot for pSTAT3 expression in
the lungs of saline and SalB-dosed rats and the treatment group comparison by
densitometry analysis. The two weeks pulmonary administration of SalB at 0.2 mg/kg
elevated the lung tissue expression of pSTAT3 by 1.8–fold, compared to the saline-dosed
control (p<0.05). Likewise, as shown in Figure 3.5 (B), SalB administration also showed
an increased VEGF expression by 1.6 -fold. However this increase did not reach
significance, presumably due to their high variability. It appears, however, that SalB at
0.2 mg/kg was likely sufficient to activate STAT3 and stimulate VEGF in the lung tissues
with pulmonary administration. It should be noted that this SalB treatment did not impair
treadmill exercise endurance or cause abnormality of the airspace, as described in
Chapter 5. Therefore, SalB at 0.2 mg/kg has been chosen for the therapeutic reversal
activity assessments in the in vivo rat models of established emphysema in Chapter 5.
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Figure 3.3: Lung tissue expression of cytoplasmic pSTAT3 (A) and VEGF (B) in healthy rats
dosed with saline or SalB at 0.2 mg/kg, as indicated by representative bands at 75 and 25 kDa.
Data: mean±SE (n=3 or 5) (+) present; (-) absent. * p<0.05, compared to the saline control by
two-tailed t-test.
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3.4. Conclusions
SalB showed the potent free radical scavenging activity with IC50 of 3.67 µM, but
was devoid of the anti-elastase activity. In rats, pulmonary administration of SalB at 0.2
mg/kg appeared to elevate the lung expression of pSTAT3 and VEGF. Therefore, unlike
the “triple-threat” inhibitors, SalB would fall under a different mechanistic class of
compounds targeting VEGF stimulation to treat emphysematous lung damage. This
VEGF stimulation appeared to arise from STAT3 activation, as reported previously
elsewhere (Liu et al. 2014).
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CHAPTER 4
IN VITRO CHARACTERIZATION OF ANTI-CELL DEATH, CELL
PROLIFERATION, MIGRATION AND RECRUITMENT STIMULATORY
ACTIVITIES OF SALVIANOLIC ACID B (SalB)

4.1 Introduction
As described in Chapter 1, progressive destruction and loss of alveolar septal
structures in emphysema is thought to be a result of an imbalance between induced cell
death and suppressed cell proliferation, migration and recruitment in the lung. In this
context, VEGF has received considerable attention by the virtue of its regulatory
activities in the alveolar epithelial and endothelial cell survival, proliferation, migration
as well as trans-endothelial recruitment of circulating stem cells to the lungs (Takahashi
et al. 2005; Caiado & Dias 2012). In fact, the lung tissue level of VEGF was reduced in
patients with emphysema/COPD; and VEGF receptor blockade caused lung cell death
and emphysematous structural damages in animals (Yasuo et al. 2011; Kasahara et al.
2000). Therefore, pharmacological recovery of VEGF may enable reversal of this lung
cellular pathobiologic imbalance, and thereby repair of the alveolar structural destruction
in emphysema.
Salvianolic acid B (SalB) has been reported to stimulate VEGF as a result of
activation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3
(STAT3) in vitro (Liu et al. 2014). In Chapter 3, SalB at a dose of 0.2 mg/kg was shown
to increase the lung tissue expression of pSTAT3 and VEGF in vivo, in addition to its
potent anti-oxidation activity. Accordingly, in this chapter, SalB was assessed in the lung
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alveolar epithelial (A549) and endothelial (HMVEC-L) cell systems to examine its
activities in 1) protecting cells against oxidative stress and VEGF receptor blockade –
induced cell death; 2) stimulating cell proliferation and migration; and 3) promoting
trans-endothelial stem cell recruitment. Pharmacologic inhibitors of JAK2, STAT3 and
VEGF were then used to assess the JAK2, STAT3 and VEGF -dependent mechanisms.
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4.2.Materials and Methods
4.2.1. SalB and inhibitors
SalB (Ivy Fine Chemicals) was stored at room temperature in a desiccator with
silica gel and freshly prepared as a 1 mM (0.718 mg/ml) aqueous solution before each
experiment. SU5416, a VEGF receptor antagonist, was a gift from Dr. Voelkel (VCU
Pulmonary Medicine) and stored at -20oC prior to use. SU5416 stock solution (20 mM)
was prepared in dimethylsulfoxide (DMSO; Sigma-Aldrich) that had been degassed by
purging N2 gas for 5 min. AG490 (Tyrphostin; Sigma-Aldrich) was used as a tyrosine
kinase inhibitor of JAK2, while S31-201 (Sigma-Aldrich) as an inhibitor of STAT3
phosphorylation and dimerization (Hermann et al. 2009; Park et al. 2014). These
inhibitors were prepared as 50 mM and 68 mM stock solutions in degassed DMSO and
stored as 50 µl aliquots at -20 ˚C and -80 ˚C, respectively.

4.2.2 Lung alveolar epithelial, endothelial and mesenchymal stem cell culture
Human alveolar epithelial A549 cells (American Type Culture Collection; ATCC,
Manassas, VA) were cultured in the Dulbecco's Modified Eagle's medium/F-12 (ATCC)
supplemented with 10 % fetal bovine serum (FBS; Gibco-Australia) and 1 % Penicillinstreptomycin (ATCC); propagated in the 25 or 75 cm2 culture flasks (Corning Costar;
Cambridge, MA) according to the ATCC’s protocol [Product Information Sheet, ATCC];
and used between 20-30 of the passages. Human pulmonary microvascular endothelial
cells (HMVEC-L) cells (Lonza, Walkersville, MD) were cultured in the endothelial cell
growth medium (Lonza) with growth factors, cytokines and supplements (Lonza); grown
in the 75 cm2 culture flasks, according to the Lonza’s protocol; and used between 5-9 of
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the passages. Bone marrow derived human mesenchymal stem cells (MSCs; Roosterbio,
Frederick, MD) were cultured in DMEM/F12, GlutaMAX (Thermo) supplemented with
10 % FBS; propagated in the 75 cm2 culture flasks, according to the Roosterbio’s
protocol; and used between 3-6 of the passages. These cell cultures were maintained in a
humidified atmosphere of 5 % CO2/95 % air at 37 °C in the incubator (CO2 cell standard,
BMT USA, LLC, Monroe, WA). The culture media were replaced three times in a week
and the cells were passaged upon reaching 90 % confluence, monitored under the
microscope (Nikon-TMS phase contrast microscope, Image Systems Inc., Columbia,
MD).

4.2.3 Anti-cell death activity assessments
The in vitro protective activities of SalB and their JAK2 and STAT3 dependence
were assessed in the A549 and HMVEC-L cells against cell death induced by oxidative
stress and/or VEGF-receptor blockade, using the trypan blue exclusion assay and
propidium iodide (PI)-based flow cytometry. The procedure followed, that developed
previously (Truong 2016), with slight modifications. Trypan blue reagent (4 %; Amresco,
Solon, OH) was sterile-filtered using the 0.2 µm syringe filter (Corning) before use. The
A549 and HMVEC-L cells were plated on to the 24 or 48-well plates at a density of 0.15
x 106 cells/well. Cell death was induced with 0.1 mM hydrogen peroxide (H2O2; Acros
Organics, New Jersey, NJ) or 20 µM SU5416 over 24 h. SalB was added at 1, 10 or 25
µM and co-incubated with H2O2 or SU5416 to examine its protective activities against
H2O2–induced oxidative cell death and SU5416–induced apoptotic cell death (Kasahara
et al. 2000). The media were used as the control vehicle. In some experiments, AG490 at
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25 µM or S31-201 at 50 or 100 µM was co-incubated with SalB at 25 µM, while cell
death was induced with SU5416 for 24 h to examine whether SalB’s anti-cell death
activities depend on JAK2 and STAT3, respectively. At 24 h, % cell death was
determined in each well by the trypan blue exclusion assay or by the PI-based flow
cytometry. For the trypan blue exclusion assay, following trypsinization, the cell
suspension was centrifuged at 12,000 rpm (Eppendorf centrifuge 5415 C, Hauppauge,
NY) for 2 min. The cell pallet was re-suspended and incubated in the 4 % trypan blue
solution at room temperature for 3-5 min. The cells were again centrifuged, re-suspended
in the fresh medium, plated on to 24 –well plates and allowed to settle for 30 min. In each
well, over 300 cells were differentiated and counted as stained dead cells and unstained
live cells under the microscope (Omax, Kent, WA), to calculate % dead cells from:

% !"#! !"##$ =

!ℎ! !"#$%& !" !"#! !"##$
! 100
!ℎ! !"!#$ !"#$%& !" !"#$ !"# !"#! !"##$

For the flow cytometry assay, at 24 h of the H2O2 –induced cell death with or
without SalB incubation, the cells were trypsinized, re-suspended at 1x106 cells/ml in 100
µl of media, and incubated with 5 µl of PI reagent of the FITC Annexin V Apoptosis
detection kit I (BD Biosciences, San Diego, CA) at room temperature for 15 min.
Following 5-times dilution with the assay buffer of the kit, over 10,000 cells were
introduced into the Attune flow cytometer (Thermo Fisher Scientific) and sorted,
according to 488 and 617 nm of the excitation and emission wavelengths, respectively.
Note that proper performance of the flow cytometer had been ensured before each assay
using CytoFLEX Daily QC fluorospheres (Beckman-Coulter, Brea, CA) as a quality
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control test. Using the Attune NxT software, cells were gated to exclude the debris and
clumps, and then sorted with respect to PI fluorescence signal set at a threshold of 2 x
104, i.e., the cells exceeding this threshold of the fluorescence intensity were counted as
PI-positive dead cells to calculate the % cell death in each well.

4.2.4. Cell proliferation activity assessment
The A549 and HMVEC-L cell proliferation activities were measured by the MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (Cayman Chemical
Company) and BrdU (5-bromo-2-deoxyuridine) assay (Biovision Milpitas, CA). In 96well plates, 0.02 or 0.04 x 106 cells were plated and allowed to settle overnight.
Subsequently, the A549 cells were treated with SalB at 0, 10 or 25 µM in FBS
suppressed (2 %) media for 0-48 h; and the HMVEC-L cells were treated with SalB at 0,
5, 10 or 25 µM in the growth media for 0-48 h. In the MTT assay, the MTT reagent (10
µl of 5 mg/ml) was added to 100 µl of the incubation media at 4 h before the end of
treatment. At 48 and 24 h, respectively, the incubation media were removed, and replaced
with 0.04 N HCl in isopropanol crystal dissolving solution (prepared in-house), for 15
min. The 570 nm absorbance (Abs570) was then measured using a microplate reader
(BioTek, Winooski, VT). In some studies, JAK2, STAT3 and VEGF inhibitors, AG490,
S31-201 and SU5416 were co-incubated at 25, 50 or 100, and 5 µM, respectively, with
SalB at 25 µM to examine the mechanism of SalB’s cell proliferation stimulatory
activities. Additionally, in the HMVEC-L cells, the cell proliferation activity of SalB was
also measured with the BrdU activity, according to the kit protocol. Following 20 h
incubation, the BrdU–labeled proliferative cells were quantified with the 450 nm
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absorbance (Abs450) measured using the microplate reader.

4.2.5. Cell migration activity assessment
The cell migration activities were determined using an in vitro scratch wound
closure assay established and validated in house according to a method previously
described by Liang et al. (2007). The HMVEC-L and A549 cells were seeded at 0.4 x 106
M cells/well on a 6-well plate and grown to confluence. The cell monolayers were
scratched using a 200 µl pipette tip and incubated with SalB (2.5, 5, 10, 25 µM) or the
vehicle for 12 and 48 h, respectively. In the A549 cells, a serum-suppressed medium (2%
FBS) was used. Guided by the markings made on the well plate, images of the scratch
wound were taken at 3 different points in each well. Pre- and post-incubation scratch
wound areas (WApre and WApost) were measured using ImageJ (NIH). For each treatment
group, 3 wells were used. The percent wound closure was calculated using the equation:

% !"#$% !"#$%&' =

!"!"# − !"!"#$
! 100
!"!"#

In some experiments, to clarify the mechanism of SalB’s activity, AG490 (25 µM), S31201 (50 or 100 µM) or SU5416 (5 µM) were co-incubated with SalB to examine JAK2STAT3 and VEGF dependence on the SalB’s cell migration promotion activity.

4.2.6. Trans-endothelial migratory stem cell recruitment activity assessment
The MSC recruitment into the lung through the endothelial barrier was modeled
using the in vitro trans-endothelial migration assay. The method originated from Muller
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and Luscinskas (2008) and modified for use in MSC migratory recruitment. It was
established in-house to determine SalB’s activity in promoting stem cell recruitment.
Human fibronectin (Corning) was prepared as a 1 mg/ml stock solution by reconstitution
in distilled water and stored at -20 ˚C prior to use. This stock solution was diluted 20
times with HEPES buffer (Lonza) from which 50 µl was applied to coat each of the
Fluoroblock 8.0 µm transwell® filters (Figure 4.1 (A), 0.3 cm2 area, Corning), according
to the instructions. The HPMVEC-L cell monolayers was grown on the fibronectincoated filters upon seeding of 30,000 cells on each filter, as shown in Figure 4.1 (B).
Upon confluence, typically on day 5, the trans-endothelial electrical resistance (TEER)
was measured using the volt-ohmmeter and STX-2 electrodes (EVOM; World Precision
Instruments, Sarasota, FL) and ensured to be in a range of 85-90 Ωcm2 (ohms cm2), as
reported by Sedgwick et al. (2002). DiIC12(3) fluorescent dye (Corning; 100 mg/ml
stock solution prepared in degassed DMSO and stored at -20 ˚C; 549/565 nm,
Excitation/Emission) was used at 0.5 µg/ml to stain the MSCs in culture for 2 h,
according to the supplier’s instructions, and the labeling efficiency and duration were
determined prior to the use. Subsequently, the DiIC12-labeled MSCs were trypsinized
from which 50,000 cells were added onto the HMVEC-L cell monolayers of the
fluoroblock transwell filters. Initial experiments determined the DiIC12-labeled MSC
migration over 24 h in the presence or absence of SalB at 25 µM or 30 % FBS in the
basolateral side, as shown in Figure 4.1 (C). By contrast, in the subsequent experiments,
the HMVEC-L cell monolayers was pre-treated with SU5416 at 5 µM for 2 h followed by
addition of MSCs with or without SalB at 25 µM to assess the impaired MSC recruitment
due to VEGF receptor blockade and its recovery with SalB. At 24 h of migration, the
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apical side of the transwell was washed 3 times with sterile PBS (Quality biological,
Gaithersburg, MD), and the MSC and HMVEC-L cells on the apical side were swabbed
using a cotton swab. After the inserts were flipped over, the cells on the basolateral side
of the transwell filter were fixed for 15 min with 4 % paraformaldehyde (Sigma-Aldrich)
solution in PBS. The filters were carefully cut and mounted on glass slides. The
basolateral side of the fluoroblock filters was then observed under the fluorescence
microscope (Olympus 1X51, Center Valley, PA). Five 100X images were taken for each
filter, accounting for the 20 % of the filter area. DiIC12-labeled MSCs were counted in
each image using ImageJ (Appendix 3). The total number of MSCs migrated to the
basolateral side were calculated as 5 times the total cells counted by ImageJ from the 5
filter images. Percent cells migrated was calculated by using the equation:

% !"#$%&'( =

!"#$% !"#$%& !" !"#$ !"#$%&'( !" !ℎ! !"#$%"&'("% !"#$
× 100
50,000 (!"#$%& !" !"#$ !""#" !" !ℎ! !"#$!% !"#$)
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HMVEC-L
monolayer

DilC12-labelled
MSCs
SU5416
Fibronectin
Vehicle/ SalB (25 µM)/
FBS (30 %)

Figure 4.1: (A) Fluoroblock transwell insert (B) Florescence microscope image (100X) of DilC12labelled HMVEC-L monolayer grown on the fibronectin-coated fluoroblock transwell filter (C)
Schematic representation of the trans-endothelial migration assay showing cross section of the
fluoroblock insert transwell.
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4.2.7. Data description and statistical analyses
The results of SalB’s in vitro activities were expressed as mean±SD (n=3-9).
Statistical analyses for group comparison were carried out using Prism® 7 (GraphPad
Software, San Diego, CA) or JMP-Pro® 12 (SAS Institute, Inc., Cary, NC) by one-way
analysis of variance (ANOVA). Post-hoc analysis for multiple comparison testing was
performed by the Tukey’s or Dunnett’s method, the latter being used to compare multiple
test groups to the vehicle control group and not among each other. p<0.05 was considered
as significant.
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4.3. Results
4.3.1. Anti-lung cell death activities of SalB
In vitro inhibitory activities of SalB against alveolar epithelial A549 cell death
induced with 0.1 mM H2O2, i.e. oxidative stress, were determined using the trypan blue
exclusion and PI –based flow cytometry assays, as shown in Figures 4.2 and 4.3,
respectively. H2O2 -induced A549 cell death by 6.5 –fold (p<0.05), by the trypan blue
exclusion assay (Figure 4.2). However, SalB significantly inhibited this induced cell
death by 80.1 % with 10 µM and by 86.0 % with 25 µM (p<0.05), but not with 1 µM,
while SalB at 25 µM alone did not induce cell death (Figure 4.2). This concentrationdependent anti-cell death activity of SalB could be reasonably attributed to negated
oxidative insult with the SalB’s anti-oxidative activity shown in Chapter 3 (IC50 = 3.7
µM, Figure 3.1). Figure 4.3 (A and B) shows the H2O2 –induced A549 cell death and its
inhibition with SalB at 25 µM, determined by the PI –based flow cytometry assay. As
seen with the trypan blue exclusion assay, H2O2 -induced cell death by 5.9 –fold, to
which SalB exhibited a significant 59.2 % inhibition (p<0.05).
SalB at 25 µM was also examined against A549 cell death induced by VEGFreceptor blockade using SU5416. As shown in Figure 4.4 (A), SU5416 at 10 and 20 µM
induced cell death by 1.8 –fold and 3.6 –fold, respectively (p<0.05); and SalB at 25 µM
inhibited SU5416-induced cell death by 121.8 % and 88.4 %, respectively (p<0.05).
AG490 and S31-201 were then respectively added as JAK2 and STAT3 inhibitors, to
examine their counter effects on the SalB’s anti-cell death activities. As shown in Figure
4.4 (B), AG490 and S31-201 each blocked the SalB’s anti-cell death activities by 96.8 %
and 68.2 %, respectively (p<0.05). It should be noted that these inhibitors alone did not
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cause cell death in SU5416 –treated A549 cells, as validated in Table 4.1.
Likewise, as shown in Figure 4.5, in the HMVEC-L cells, SU5416 at 20 µM
induced cell death by 3.3 –fold and that cell death was inhibited with SalB at 25 µM
significantly by 47.7 %. Moreover, AG490 and S31-201 inhibited the SalB’s anti-cell
death activity by 85.8 % and 131.2 %, respectively (p<0.05). Therefore, SalB was
potently (i.e., at 25 µM) cytoprotective against lung epithelial (A549) and endothelial
(HMVEC-L) cell death induced with VEGF receptor blockade (SU5416) in a JAK2 and
STAT3 –dependent mechanism.
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Figure 4.2: In vitro anti-cell death activities of SalB at 1, 10 and 25 µM against H2O2 -induced cell
death in the A549 cells, determined by the trypan blue exclusion assay. Data: mean±SD (n=3 - 6)
(+) present; (-) absent *p<0.05, compared to vehicle treated/induced control; #p<0.05, compared to
the H2O2 -induced and vehicle treated cells, by ANOVA and Tukey’s multiple comparison test.
SalB at 25 µM alone did not cause significant cell death.
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Figure 4.3: In vitro anti-cell death activities of SalB at 25 µM against H2O2 -induced cell death in the
A549 cells, determined by PI –based fluorescence flow cytometry; (A) Representative PI –based cell
population histograms. (B) % of PI positive cells, following vehicle or H2O2 –induction and vehicle or
SalB treatment. The cells in the horizontal range in Panel A were counted as PI positive dead cells.
Panel B: Data: mean±SD (n=3) (+) present; (-) absent *p<0.05, compared to the vehicle –
treated/induced control; #p<0.05, compared to the H2O2 induced and vehicle treated cells, by ANOVA
and Tukey’s multiple comparison test.
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Figure 4.4: (A) In vitro cytoprotective activities of SalB at 25 µM against cell death induced by
SU5416 at 10 or 20 µM in the A549 cells with or without AG490 (25 µM) or S31-201 (100 µM),
determined by the trypan blue exclusion assay; (B) Effect of AG490 or S31-201 addition on
SalB’s anti-cell death activity. Data: mean±SD (n=3) (+) present; (-) absent *p<0.05, compared to
the vehicle-treated/induced control; #p<0.05, compared to SU5416 -induced and vehicle treated
cells, by ANOVA and Tukey’s multiple comparison test. Panel B: no significant difference in the
SU5416 -induced cells between the vehicle treatment and the SalB treatment co-incubated with
AG490 or S31-201.
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Figure 4.5: In vitro cytoprotective activities of SalB at 25 µM against cell death induced with
SU5416 at 20 µM in the HMVEC-L cells with or without AG490 (25 µM) or S31-201 (50
µM), determined by the trypan blue exclusion assay (A) SU5416 induced cell death and its
inhibition with SalB; (B) Effect of AG490 or S31-201 addition on SalB’s anti-cell death
activity. Data: mean±SD (n=3-5) (+) present; (-) absent *p<0.05, compared to vehicle control;
#p<0.05, compared to SU5416 induced cell death, by ANOVA and Tukey’s multiple
comparison test. Panel B: no significant difference in the SU5416 -induced cells between the
vehicle treatment and the SalB treatment co-incubated with AG490 or S31-201.
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Table 4.1: Effects of AG490 and S31-201 on the SU5416 –induced A549 cell death.
Cell type

A549

Treatment

SU5416

Inhibitor

% Cell death

-

6.1 ± 0.78

AG490

5.3 ± 0.94

S31-201

5.8 ± 0.42

Data: mean±SD (n=3-4). No significant difference in the SU5416 –induced A549 cell
death following the vehicle treatment and the AG490 or S31-201 treatment.
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4.3.2. Lung cell proliferation stimulatory activities of SalB
Figure 4.6 shows the in vitro A549 cell proliferation activities following 24 or 48
h treatment with SalB at 10 or 25 µM or the vehicle with or without addition of AG490,
S31-201 or SU5416, determined by the MTT assay. Upon confirmation of continued cell
proliferation over 48 h (as shown in Panel A), SalB was found to stimulate A549 cell
proliferation over 48 h in a concentration –related manner and significantly by 3.4 –fold
at 25 µM (p<0.05), as shown in Panel B. However, this A549 cell proliferation
stimulatory activity was entirely diminished by co-incubation with AG490, S31-201 and
SU5416, as shown in Panel C, thereby respectively suggesting its JAK2, STAT3 and
VEGF –dependent mechanism. Note that these inhibitors alone had no effect on the A549
cell proliferation activities (Panel C).
Likewise, Figure 4.7 shows the in vitro HMVEC-L cell proliferation activities
following 24 or 48 h treatment with SalB at 5-50 µM or the vehicle with or without
addition of AG490, S31-201 or SU5416, determined by the MTT assay. Again, upon
confirmation of continued cell proliferation over 48 h (as shown in Panel A), SalB was
found to stimulate HMVEC-L cell proliferation over 24 h in a concentration –related
manner and significantly by 1.8 and 1.9 –fold at 25 and 50 µM (p<0.05), respectively, as
shown in Panel B. However, the HMVEC-L cell proliferation stimulatory activity of SalB
was also diminished significantly by 62.9, 144.3 and 94.3 % (p<0.05), when AG490,
S31-201 and SU5416 were co-incubated with SalB at 25 µM, again suggesting its JAK2,
STAT3 and VEGF –dependent mechanism. Note that these inhibitors alone had no
effects on HMVEC-L cell proliferation (Panel C).
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The cell proliferation stimulatory activities of SalB were further confirmed in the
HMVEC-L cells, determined with the 450 nm absorbance (Abs450) by the BrdU assay, as
shown in Figure 4.8. SalB at 25 µM was shown to result in a significantly higher Abs450
by 1.4 –fold (p<0.05), compared to the vehicle -treated cells. Taken all together,
therefore, SalB was potently (i.e., at 25 µM) stimulatory to the lung epithelial (A549) and
endothelial (HMVEC-L) cell proliferation in a JAK2, STAT3 and VEGF –dependent
manner.
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Figure 4.6: In vitro cell proliferation activities in the A549 cells following various treatments
determined with the 570 nm absorbance (Abs570) by the MTT assay (A) following 0, 24 and 48 h
incubation; (B) following 48 h of treatment with SalB at 10 or 25 µM or the vehicle, relative to at
0 h of plating; (C) following 48 h treatment with SalB at 25 µM or the vehicle, co-incubated with
or without AG490 (25 µM), S31-201 (100 µM) and SU5416 (5 µM). Data: mean±SD (n=4-7) (+)
present; (-) absent *p<0.05, compared to vehicle-treated control; #p<0.05, compared to the 25 µM
SalB -treated cells, by ANOVA and Tukey’s or Dunnett’s multiple comparison test.
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Figure 4.7: In vitro cell proliferation activities in the HMVEC-L cells following various treatments
determined with the 570 nm absorbance (Abs570) by the MTT assay (A) following 0, 24 and 48 h
incubation; (B) following 48 h of treatment with SalB at 10 or 25 µM or the vehicle, relative to at 0
h of plating; (C) following 48 h treatment with SalB at 25 µM or the vehicle, co-incubated with or
without AG490 (25 µM), S31-201 (100 µM) and SU5416 (5 µM). Data: mean±SD (n=4-11) (+)
present; (-) absent *p<0.05, compared to vehicle-treated control; #p<0.05, compared to the 25 µM
SalB -treated cells, by ANOVA and Tukey’s or Dunnett’s multiple comparison test.

53

0.6

Abs450

*
0.4

0.2

0.0

SalB (µM)

-

+10

+25

Figure 4.8: In vitro cell proliferation activities in HMVEC-L following 24 h treatment with
SalB at 10 or 25 µM or the vehicle, determined with the 450 nm absorbance (Abs450) by the
BrdU assay. Data: mean±SD (n=4); (-) absent *p<0.05, compared to vehicle control, by
ANOVA and Dunnett’s multiple comparison test.
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4.3.3. Lung cell migration promoting activities of SalB
Figures 4.9 – 4.11 show the result of the in vitro scratch wound closure studies in
the confluent A549 cells with or without SalB and /or the inhibitors. As shown in Figure
4.9, the cell scratch wounds made at 0 h were gradually closed over 48 h. The wound
areas were determined as the areas without cell coverage identified by using Image J to
accurately trace the wound boundaries, as shown in Figure 4.10 (A). Thus, Figure 4.10
(B) shows % wound closure at 48 h of different treatments. SalB promoted the wound
closure in a concentration-related manner, and significantly by 1.5 –fold at 25 µM
(p<0.05). However, this promoted wound closure with SalB at 25 µM was opposed with
AG490 (25 µM), S31-201 (100 µM) and SU5416 (5 µM) significantly by 108.8, 47.7 and
85.2 %, respectively (p<0.05; Figure 4.11). Because these inhibitors alone did not affect
the wound closure, SalB’s wound closure promoting activities were suggested to depend
on JAK2, STAT3 and VEGF, like its anti-cell death and cell proliferation stimulatory
activities (Figures 4.4-4.7).
Similarly, Figures 4.12-4.15 show the results of the in vitro scratch wound
closure studies in the confluent HMVEC-L cells with or without SalB and/or the
inhibitors. The cell scratch wounds made at 0 h were gradually closed over 18 h, as
shown in Figures 4.12 and 4.13. The wound areas were determined at 12 h via the
accurate tracing of wound boundaries (Figure 4.13 (A)) to calculate % wound closure
following different treatments. Figure 4.13 (B) shows the time course of % wound
closure in the HMVEC-L cells treated with the vehicle or SalB at 10 µM. SalB at 10 µM
accelerated the wound closure, compared to the vehicle treatment. As shown in Figure
4.14, SalB promoted the wound closure in a concentration–dependent manner and
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significantly at ≥ 5 µM (p<0.05). At 25 µM, SalB showed a 1.6 –fold greater % wound
closure, relative to the vehicle –treated control (P<0.05). Figure 4.15 shows % wound
closure with SalB at 25 µM and its significant inhibition with AG490, S31-201 and
SU5416 by 75.3, 92.9 and 77.7 %, respectively. It should be noted that, % wound closure
appeared to be cell passage dependent as 23.1 % and 42.9 % of wound closure was seen
with passage 9 and 6, respectively.
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Vehicle control

SalB (25 µM)

Figure 4.9: Representative images of linear scratch wounds made at 0 h and their closures at 24
and 48 h in the A549 cells in three different wells, treated with the vehicle or SalB at 25 µM.
The linear dotted lines are to demonstrate cell wound closure over 48 h. The wound areas were
calculated by tracing wound boundaries like Figure 4.10 (A).
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Figure 4.10: (A) Representative images of linear scratch wound at 0 and 48 h of the treatment
with the vehicle or SalB at 25 µM in the A549 cells; (B) % wound closure in the A549 cells
following 48 h treatment with the vehicle or SalB at 10 and 25 µM. Data: mean±SD (n=7-8) (-)
absent *p<0.05, compared to vehicle -treated control, by ANOVA and Dunnett’s test.
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Figure 4.11: In vitro % wound closure at 48 h in the A549 cells with or without SalB at 25 µM
and/or inhibitors: (A) Effect of AG490 (25 µM) or S31-201 (100 µM); and (B) Effect of
SU5416 (5 µM). Data: mean±SD (n=3-6) (+) present; (-) absent *p<0.05, compared to vehicle –
treated control; #p<0.05, compared to the SalB (25 µM) –treated cells, by ANOVA and Tukey’s
multiple comparison test. Addition of AG490, S31-201 or SU5416 alone did not alter % wound
closure, relative to the vehicle –treated control.
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Figure 4.12: Representative images of linear scratch wounds made at 0 h and their closures at 12
h in the HMVEC-L cells in three different wells, treated with the vehicle or SalB at 25 µM. The
linear dotted lines are to demonstrate cell wound closure over 12 h. The wound areas were
calculated by tracing wound boundaries like Figure 4.13 (A).
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Figure 4.13: (A) Representative images of the linear scratch at 0 and 12 h of the treatment with
the vehicle or SalB at 25 µM in the HMVEC-L cells; (B) Time course changes of the % wound
closure over 18 h during the treatment with the vehicle or SalB at 10 µM in the HMVEC-L cells
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Figure 4.14: In vitro % wound closure in the HMVEC-L cells following 12 h treatment with
SalB at 2.5 – 25 µM or the vehicle. Data: mean±SD (n=3-10) (+) present *p<0.05, compared to
vehicle control, by ANOVA and Dunnett’s multiple comparison test.
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Figure 4.15: In vitro % wound closure in the HMVEC-L cells treated with or without SalB at 25
µM and/or inhibitors: (A) Effect of AG490 (25 µM) and (B) Effect of S31-201 (100 µM) or
SU5416 (5 µM). Data: mean±SD (n=3-9) (+) present; (-) absent *p<0.05, compared to vehicle treated control; #p<0.05, compared to the SalB (25 µM) –treated cells, by ANOVA and Tukey’s
multiple comparison test. Addition of AG490, S31-201 and SU5416 alone did not alter the %
wound closure, relative to the vehicle –treated control.
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4.3.4.Stem cell recruitment promoting activities of SalB
Figure 4.16 shows % of MSCs migrated from the apical side to the basolateral
side of the fluoroblock transwell filters with or without the HMVEC-L monolayers over
24 h. Despite physically a barrier, the HMVEC-L monolayers promoted MSC migration
significantly by 1.3 –fold (p<0.05), suggesting an active role of the endothelial cells in
the MSC migratory recruitment. Figure 4.17 shows the trans-HMVEC-L cell monolayer
migratory recruitment of MSCs over 24 h in the absence or presence of 30 % FBS. As
similarly shown by Luscinskas (2008), FBS promoted MSC migration significantly by
1.6 –fold (p<0.05), thus successfully validating this newly developed system to assess the
trans-endothelial MSC migration. Accordingly, Figure 4.18 shows the results of transHMVEC-L cell monolayer migratory recruitment of MSCs with or without SU5416
and/or SalB treatment. The microscopic images of MSCs migrated to the basolateral side
of the fluoroblock filters were converted to the dot cell images for counting using ImageJ,
as shown in Figure 4.18 (A). Upon SU5416 treatment, MSC migration was decreased
significantly by 51.7 % (p<0.05), as shown in Figure 4.18 (B). However, SalB at 25 µM
recovered this MSC migration activity by 60.0 % (p<0.05), while it alone did not affect
MSC migration. It was clear therefore that SalB potently (i.e., at 25 µM) restored the
trans-endothelial MSC recruitment impaired as a result of VEGF receptor blockade.
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Figure 4.16: % of MSCs migrated through the fluoroblock filters to the basolateral side with or
without the HMVEC-L monolayers at 24 h. Data: mean±SD (n=3) (+) present; (-) absent *p<0.05,
compared to the MSC migration in the absence of the HMVEC-L cell monolayers, by one -sided ttest.
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Figure 4.17: Trans-HMVEC-L cell monolayer migration of MSCs in 24 h with or without 30 %
FBS. Data: mean±SD (n=3) (+) present; (-) absent *p<0.05, compared to the MSC migration in the
absence of FBS, by one -sided t-test.
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Figure 4.18: (A) Representative images of MSCs migrated to the basolateral side of the
Fluoroblock transwell insert under fluorescence microscope (Left panel) and fluorescent cells
counted by Image J in each of the microscopic image (Right panel) (100X).
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Figure 4.18: (B) Trans-HMVEC-L cell monolayer migration of MSCs in 24 h with or without
SalB at 25 µM and/or SU5416 (5µM) pretreatment. Data: mean±SD (n=3-6) (+) present; (-)
absent *p<0.05, compared to vehicle-treated control; #p<0.05, compared to SU5416 pretreated
and vehicle-treated cells, by ANOVA and Tukey’s multiple comparison test.
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4.4. Discussion
In this chapter, a series of in vitro methods have been used to assess cell-specific
VEGF-dependent pharmacological activities of SalB. Lung alveolar epithelial type II
A549 cells and endothelial HMVEC-L cells were studied in the trypan blue exclusion and
propidium iodide (PI) –based flow cytometry assays to evaluate the anti-cell death
activities of SalB against induced oxidative stress and VEGF receptor blockade. Cell
proliferation and migration stimulatory activities of SalB were assessed using the MTT or
BrdU assay and the in vitro scratch wound closure assay, respectively. SalB showed
potent (i.e., at 10-25 µM) anti-cell death, cell proliferation and migration promoting
activities, which appeared to be related to the JAK2-STAT3-VEGF signaling pathway,
since the inhibitors to this pathway suppressed SalB’s stimulatory effects. Subsequently,
a novel trans-endothelial migration assay was developed to study the effect of SalB on
the recruitment of MSCs through the lung endothelium. SalB at 25 µM was able to
correct the VEGF receptor blocker -induced impairment in the trans-endothelial
migration of MSCs in this assay. This unique ability of SalB is promising in studying
lung repair in emphysema, which is characterized by reduced alveolar cell survival,
proliferation, migration and recruitment (Song et al. 2010).
4.4.1. SalB protects lung epithelial and endothelial cells from oxidative stress and VEGFreceptor blockade
Cigarette smoke is a major causative factor in COPD and contains oxidants that
have the ability to induce lung cell death when accompanied by the depletion of
pulmonary antioxidants resulting in an oxidant/antioxidant imbalance and emergence of
oxidative stress (Demkow 2009; Li et al. 2013). Thus, protecting lung cells from
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oxidative stress and improving their survival are a key to halting the ongoing alveolar
destruction. As described in Chapter 3, SalB has a potent anti-oxidant radical scavenging
activity with IC50 of 3.67 µM (Figure 3.1). Thus we hypothesized that SalB will have
protective effects against oxidative cell death. Accordingly, SalB showed concentration
related anti-cell death activity against 0.1 mM H2O2 –induced oxidative stress in A549
cells, significantly inhibiting cell death at 25 µM by 86.0 % and 59.2 % (p<0.05) by the
trypan blue exclusion assay and the PI based flow cytometry assay, respectively. While
the trypan blue exclusion assay offers the advantages of sensitivity and robustness, the
flow cytometry assay has the advantage of a more objective analysis (Vermes et al.
1995). In both these independent studies, SalB at 25 µM showed significant anti-cell
death activities against induced oxidative stress.
Increased apoptosis of alveolar septal cells in emphysema, at least in part, due to
the depletion of VEGF -a survival factor for both epithelial and endothelial cells, has
been widely reported (Brusselmans et al. 2005; Kanazawa et al. 2003; Imai et al. 2005).
Therefore, SalB’s cytoprotective activities were studied against emphysematous celldeath induced by SU5416, a competitive inhibitor of VEGF, to mimic the impaired
VEGF signaling conditions (Kasahara et al. 2000). SU5416 at 20 µM (VEGF-receptor
inhibition IC50 = 7 µM) induced 3.6 and 3.3 –fold (p<0.05) cell death in A549 and
HMVEC-L cells, respectively by the trypan blue exclusion assay. SalB at 25 µM
inhibited this SU5416 –induced cell death in both A549 and HMVEC-L cells by 88.4 and
47.7 %, respectively (p<0.05). Given SalB’s pSTAT3 and VEGF elevating activities
(Chapter 3), JAK2-pSTAT3-VEGF signaling pathway was proposed as the mechanism of
SalB’s anti-cell death activity against SU5416. In order to study the dependence of this
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signaling pathway, inhibitors to JAK2 and STAT3, AG490 and S31-201, respectively
were co-incubated with SalB at 25 µM and were shown inhibit SalB’s anti-cell death
activities by 96.8 and 68.2 % in A549 cells and by 85.8 and 131.2 % in HMVEC-L cells,
respectively. Through this study, SalB was clearly shown to have protective effects
against two different types of emphysematous cell death induced by oxidative stress and
VEGF receptor blockade, resulting in improved cell survival.

4.4.2. SalB stimulates proliferation and migration of lung epithelial and endothelial cells
Cellular proliferation and migration are important components of the repair
process, where the former overcomes the cell loss while the later causes spreading of the
cells to restore the structure (Wagner 2003). In the adult lung, cell death is balanced with
cell proliferation and migration to maintain the alveolar structure such that an imbalance
in these processes have been suggested to result in alveolar structural destruction and
development of emphysema (Lee et al. 2012). In fact, increased cell death and decreased
cell proliferation and migration were found in the COPD/emphysema patient derived
lung epithelial cells (Perotin et al. 2014). Therefore, SalB’s repair activities in the lung
alveolar epithelial and endothelial cells were studied with respect to stimulation of cell
proliferation and migration.
SalB potently (i.e., at 10-50 µM) increased proliferation of A549 and HMVEC-L
cells by 3.5 and 1.8 –fold (p<0.05) after 48 and 24 h of treatment, respectively, by the
MTT assay. While in the MTT assay SalB at 25 µM showed a 1.3 –fold increase in
HMVEC-L cell proliferation compared to the vehicle control, in the ELISA -based BrdU
assay SalB showed a comparable 1.4 –fold increase in proliferation, thus confirming its
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proliferation stimulatory activity. SalB was also found to potently (i.e., 5-25 µM)
promote A549 and HMVEC-L cell migration by 1.5 and 1.6 –fold (p<0.05), respectively,
as compared to the vehicle control in the scratch wound closure assay. Since cell
proliferation is a critical part of wound closure, especially in the fast growing A549 cells,
SalB’s wound closure promoting activity may be a combined result of its effects on cell
proliferation and migration (Kim et al. 2010). Notably, HMVEC-L cell migration
activities were found to be passage –dependent, where older passage cells showed slower
migratory activity, as similarly shown by Liao et al. (Liao et al. 2014). While SalB was
recently shown to induce proliferation in human fibroblast cells at the concentration of
25-100 µM (Chen et al. 2014), to our knowledge, this is the first time that SalB has
shown migration promoting activity in vitro.
Inhibitors AG490, S31-201 and SU5416 were used to study the dependence of
SalB’s activities on the JAK2-pSTAT3-VEGF signaling pathway. In HMVEC-L cells,
the inhibition of STAT3 activation by S31-201 and VEGF signaling by SU5416 were
studied by the western blot analysis using primary antibodies to pSTAT3 (1:1000,
phosphorylated STAT3-Tyr705, rabbit polyclonal, #9131 Cell Signaling technology) and
pVEGFR2 (phosphorylated-VEGF receptor 2; 1:1000 rabbit polyclonal, #07-722 EMD
Millipore, Temecula, CA). Figure 4.19 (A and B) shows the reduced expression of
pSTAT3 and pVEGFR2 upon treatment with 50 µM S31-201 and 5 µM SU5416,
respectively, suggesting impaired STAT3 activation and VEGF signal transduction at the
receptor VEGFR2, thus confirming the utility of the inhibitors (Hoeben et al. 2004;
Hermann et al. 2009). In the cell proliferation assay, AG490, S31-201 and SU5416
inhibited the A549 proliferation by 84.5, 93.6 and 94.1 % and the HMVEC-L cell
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proliferation by 62.9, 144.3 and 94.3 %, respectively, suggesting the dependence of
JAK2-pSTAT3-VEGF signaling on SalB’s activities. The A549 and HMVEC-L cell
migration promotion activities of SalB were also respectively inhibited by 108.8, 47.7
and 85.2 %; and by 75.3, 92.9 and 77.7 % by AG490, S31-201 and SU5416.
In our studies we saw a dependence of SalB’s anti-cell death, proliferation and
migration activity on JAK2-STAT3-VEGF pathway. Extracellular receptor epidermal
growth factor-receptor (EGFR) carries out signal transduction through the JAK2-STAT3VEGF pathway and has been predicted to be the most probable direct target of SalB by
proteomic assay and binding affinity studies in vitro (Feng et al. 2011; Wang et al. 2008).
Therefore EGFR could be the upstream, extracellular target for SalB, especially given its
low intracellular permeability (Chen et al. 2014). However, further studies are required to
conclusively show SalB’s binding to EGFR and its effect on signal transduction.
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Figure 4.19: HMVEC-L cell (cytoplasmic) expression of pSTAT3 (A) and pVEGFR2 (B) after 24 h
treatment with S31-201 at 50 µM or SU5416 at 5 µM, respectively.
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4.4.3. SalB restores the impaired recruitment of stem cells
While the in vivo models have been used to study bone-marrow derived stem cell
recruitment in lung diseases, there are limitations to the available techniques that can
assess the stem cell recruitment in vitro (Ishizawa et al. 2004). Here, we present an in
vitro assay that is designed to model recruitment of MSCs through the microvascular
lung endothelial barrier using a transwell system. In this assay, we found that the
endothelial cells actively promoted migration of the MSCs through the monolayer, which
has also been reported previously by Becker et al. (2007). The significantly altered
permeability of the MSCs towards the permeability-inducing agent FBS was used to
validate this assay (Luscinskas 2008).
VEGF is known to stimulate the expression of stromal derived factor 1 (SDF-1), a
potent chemoattractant for stem cells, thus inducing stem cell permeability (Du et al.
2008). VEGF depletion may therefore impair the recruitment of stem cells with important
consequences in emphysema (Kurtagic et al. 2015). In our studies, VEGF receptor
blockade by SU5416 at 5 µM significantly impaired the trans-endothelial migration of
MSCs by 51.7 % (p<0.05). However, SalB at 25 µM restored this impaired migration by
60.0 % (p<0.05). These findings suggest that the VEGF signaling plays an important role
in the recruitment of stem cells and SalB corrects the SU5416 -induced impaired stem
cell recruitment, presumably because of its VEGF elevating activity. Further studies with
JAK2 and STAT3 inhibitors may be important to establish the mechanism of SalB’s
action in the stem cell recruitment.
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4.5. Conclusions
SalB exhibited the anti-cell death activities against emphysematous lung cell
death induced by oxidative stress and VEGF receptor blockade. SalB also significantly
increased proliferation and migration of lung alveolar epithelial and endothelial cells.
Additionally, the inhibitors AG490, S31-201 and SU5416 blocked SalB’s in vitro
activities. Given the pSTAT3 and VEGF elevating action of SalB shown in Chapter 3,
these findings support the hypothesis that the in vitro activities of SalB are dependent on
the JAK2-pSTAT3-VEGF signaling pathway. Furthermore, in the newly developed transendothelial migration assay, SalB was shown to recover the VEGF receptor blockadeinduced impairment in the stem cell recruitment. Therefore, SalB could show the ability
to repair alveolar structural destruction and loss by increasing lung resident cell survival,
proliferation and migration and circulating stem cell recruitment in vitro. These VEGF –
dependent pharmacological repair activities of SalB may be useful in the reversal of
emphysema, to be studied in Chapter 5.
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CHAPTER 5
SALVIANOLIC ACID B (SalB): IN VIVO REVERSAL OF EMPHYSEMA IN
RATS FOLLOWING LUNG DELIVERY

5.1. Introduction
The in vitro lung cell studies described in Chapter 4 have demonstrated that SalB
potently exerted the anti-cell death activity, stimulated cell proliferation, and promoted
cell migration at 25 µM, while recovering from impaired stem cell recruitment through
the lung endothelia. These activities appeared to be dependent on JAK2, STAT3 and
VEGF, and in vivo lung administration of SalB at a dose of 0.2 mg/kg was shown to
activate STAT3 and elevate VEGF levels in the lungs of rats, as shown in Chapter 3.
Therefore, this chapter was designed to assess the reversal activities of SalB in two
differently induced rat models of established emphysema. Specifically, emphysema was
induced and established with porcine pancreatic elastase (PPE) or cigarette smoke extract
(CSE) in rats; and SalB was then spray-instilled at 0.2 mg/kg into the lungs over three
weeks period. The reversal activities in functional treadmill exercise endurance,
morphological airspace enlargement and destruction, and lung’s cell death and
proliferation markers as well as pSTAT3 and VEGF expressions were assessed.
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5.2. Materials and Methods
5.2.1. Animals
Adult male Sprague-Dawley rats (250–275 g) purchased from Hilltop Lab were
used after 3-5 days of acclimatization, according to the animal experimental protocol
approved by the VCU’s IACUC. Rats were housed in the AAALAC- accredited animal
care facility in the Smith Building basement, maintained at 20-23 °C, 40-70 % of relative
humidity and 12-12 h light-dark cycling (the light cycle between 6 am and 6 pm). Food
and water were supplied ad libitum.

5.2.2

Protocols with PPE- and CSE -induced rat models of established emphysema
SalB (Ivy Fine Chemicals) was freshly prepared in saline as dosing solutions on

each day. A total of 35 rats were divided into 6 groups and used in two differently
induced rat models of established emphysema, as shown in Table 5.1. In the PPE-induced
model, two dose levels of SalB at 0.1 and 0.2 mg/kg were tested, while in the CSEinduced model, SalB was dosed only at 0.2 mg/kg. The experimental protocols of
emphysema induction, SalB administration, animal assessments and tissue harvest in both
models are described in Figures 5.1 and 5.2.

Table 5.1: Six experimental groups to examine the reversal activities of SalB in the PPEand CSE-induced rat models of established emphysema
Group
n
Induction
Treatment
1
10
None
Saline
2
6
PPE
Saline
3
3
PPE
SalB (0.1 mg/kg)
4
6
PPE
SalB (0.2 mg/kg)
5
5
CSE
Saline
6
5
CSE
SalB (0.2 mg/kg)
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In both models, rats were first trained for 1-2 weeks to run on the AccuPacer
rodent treadmill (Accuscan Instruments, Columbus, OH) to assess their exercise
endurance, as described in Appendix 2. In the PPE-induced model (Figure 5.1; Group 24), emphysema was induced with a single orotracheal (OT) spray-instillation of PPE (80
U/rat) following isoflurane-induced anesthesia using PennCentury’s MiscroSprayer on
day 1. PPE (135 U/mg; 95 % purity) was obtained from Elastin Products Co., as a
lyophilized powder, and its instillation solution (6 mg/ml) was also freshly prepared in
saline. Animals were left over 21 days only with treadmill training; rats in Group 1 were
left as received over 21 days, again only with treadmill training. On day 20 and 21, predose exercise endurance was measured as described below (5.2.3 Treadmill exercise
endurance) to confirm the development and establishment of emphysema with impaired
running times. Rats were then treated with 0.1 ml OT spray-instillations of saline (Group
1 and 2), SalB at 0.1 mg/kg (Group 3) or SalB at 0.2 mg/kg (Group 4), three times
weekly over three weeks period (i.e., total 9 instillations) using the MicroSprayer. On day
40 and 41, post-dose exercise endurance was measured, followed by animal sacrifice, as
described below. In the CSE-induced model (Figure 5.2; Group 5-6), emphysema was
induced over 21 days with three weekly intraperitoneal (IP) injections of CSE on day 1, 7
and 14. On each day, CSE was freshly prepared by bubbling one research-grade cigarette
3R4F (University of Kentucky, Lexington, KY) into 1 ml saline with a smoking machine.
As in the PPE-induced model, pre-dose exercise endurance was measured to confirm the
development and establishment of emphysema with impaired running times. Rats were
then treated with 0.1 ml OT spray-instillations of saline (Group 5) or SalB at 0.2 mg/kg

78

(Group 6), three times weekly over three weeks period, followed by post-dose exercise
endurance measurement and animal sacrifice, as described below.
On day 42, animals were sacrificed and lungs were harvested. Under the surgical
anesthesia with an IP injection of urethane at 1 g/kg, the trachea was cannulated through
an incision made on the neck area. The animals were sacrificed by exsanguination, and
their lung and heart were carefully removed from the body. The bronchial airway lumens
to the right lung lobes were tightly closed with a surgical suture. The left lung lobe was
then inflated through the tracheal cannula with 8-10 ml of a warm 0.5 % agarose solution
at a hydrostatic pressure of 20 cm. This solution of agarose (Invitrogen, Carlsbad, CA)
had been prepared in distilled, deionized water (DDW) at 80 ˚C and maintained at 50 ˚C
prior to use. Immediately, the lungs were placed in an ice bath for 10 min to solidify the
agarose. The right lung lobes were then removed for Western blot and myeloperoxidase
(MPO) activity analyses as described below. The inflated left lung lobe was fixed with 10
% buffered formalin (Fisher Scientific) at 4˚C for over 24 h. At the VCU Anatomical
Pathology Laboratory, the left lungs were embedded in paraffin blocks, from which 4
µm-thick lung histology sections were prepared on slides with hematoxylin and eosin
(H&E)-staining. These lung section slides were used to assess the alveoalr airspace
morphology (i.e., size and destruction) via determination of mean linear intercept (MLI)
and destructive index (DI), as described below.
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Figure 5.1: Experimental protocol used to assess the reversal activities of SalB in the PPE-induced
rat model of established emphysema. (OT, orotracheal instillation)
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Figure 5.2: Experimental protocol used to assess the reversal activities of SalB in the CSE-induced
rat model of established emphysema. (IP, intraperitoneal injection)
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5.2.3. Treadmill exercise endurance
Running times on the treadmill to exhaustion were used to measure the functional
exercise endurance for rats. Following training, as described in Appendix 2, pre-dose and
post-dose exercise endurances were measured on day 20 & 21 and 40 & 41, respectively,
on the AccuPacer rodent treadmill. Briefly, trained rats were allowed to run against a
speed of 10 m/min and an inclination of 5 degrees of the running belt. Exhaustion was
judged when the animals received a 5th electrical foot shock from the bar grid or
displayed an inability to return to the running belt. In each measurement, the exercise
endurance was reported as an average running time for exhaustion.

5.2.4. Alveolar airspace size by mean linear intercept (MLI)
Alveolar airspace size was assessed in each rat using the mean linear intercept
(MLI) measured by the method first described by Thurlbeck (Thurlbeck, 1966) and
modified in-house. Each H&E-stained alveolar section of the left lung lobe was observed
under the microscope (at 25X magnification; Nikon Optishot II equipped with Zeiss
Axiocam digital camera), and 5 microscopic images (3450 x 2585 µm) were randomly
selected and printed out. In each image, 5 horizontal lines (3450 µm) were drawn with
equal (431 µm) vertical intervals, and their intercepts with the alveolar walls were
counted to determine the MLI values (3450 mm / the number of the intercepts).
Therefore, the MLI value for each animal was calculated as an average of the 25 MLI
values (5 horizontal lines per image x 5 images).
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5.2.4. Alveolar structural destruction by destructive index (DI)
Alveolar structural destruction was assessed in each rat using the destructive
index (DI) determined by a microscopic point count technique, according to a method
described by Eidelman (Eidelman, 1991), modified in-house. In each H&E-stained
alveolar section of the left lung lobe observed under the microscope (at 100X
magnification; Nikon Optishot II and Zeiss Axiocam digital camera), 40-60 nonoverlapping fields were randomly selected and printed out. Over each image, a grid of 66
equally spaced dot points was then placed, and the alveolus lying underneath each point
was evaluated for the presence of destruction. The destruction was defined based on one
of the following criteria:
a) Two or more alveolar walls nick or defect in a single alveolus or two adjacent alveoli
opening into the same duct
b) Two or more islands of lung parenchyma within an alveolar or ductal space
c) Cuboidal epithelial lining on alveolar structure with or without nicks or defects
Each point on the alveolus was counted as either normal (N) or destroyed (D) alveolus,
based on the above criteria. Only the points falling on the whole alveoli or ducts were
counted. Over 20,000 dot points were assessed in each animal to calculate the % DI using
the equation:

% !" = 100 !

!
!+!
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5.2.6. Protein extraction and western blot analysis
After sacrifice on day 42, 300 mg of right lung tissue were minced, homogenized
using the hand homogenizer (Pro 200; Pro Scientific, Inc.) in NP-40 lysis buffer with a
cOmpleteTM protease inhibitor cocktail tablet and a PhosSTOPTM phosphatase inhibitor
tablet (Roche Diagnostics) in ice and centrifuged to obtain supernatant. For nuclear
extracts, the minced lung tissues were extracted using the Nuclear/Cytosol Fractionation
kit (Biovision) according to the manufacturer’s protocol. After determining the protein
content of the supernatant by the BCA assay, 40 µg of protein was denatured at 100 ˚C
for 10 min, electrophoresed on a 10 % Mini-PROTEAN TGX polyacrylamide gel (BioRad; Hercules, CA), and transferred to nitrocellulose membranes (0.2 mm; Bio-Rad), as
described in Appendix 2. After 1 h blocking at room temperature, the membranes were
probed via overnight incubation at 4 ˚C with each of the mouse or rabbit antibodies raised
against: 1) cleaved caspase-3 (1:1000, rabbit monoclonal, #9664, Cell Signaling,
Danvers, MA), 2) proliferating cell nuclear antigen (PCNA, 1:2000, mouse monoclonal,
#2586, Cell Signaling), 3) pSTAT3 (1:1000, phosphorylated STAT3-Tyr705, rabbit
polyclonal, #9131, Cell Signaling), 4) VEGF (1:100, mouse monoclonal, sc-7269, Santa
Cruz, Dallas, TX,), 5) b-actin (1:5,000; Sigma-Aldrich) and 6) lamin B1 (1:1000, rabbit
monoclonal, #12586, Cell Signaling). Subsequently, the membranes were incubated in
the horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibody (Bio-Rad
Laboratories) in the blocking buffer for 80 min at room temperature. The probed protein
was detected with the SuperSignal West Pico enhanced chemiluminescent substrate kit
(Pierce) in the film processor (X-Omat 2000A; Eastman Kodak, Rochester, NY). Their
band signals were quantified with ImageJ (NIH). Each protein signal was normalized
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with the corresponding ß-actin or lamin B1 signal, and expressed as the value relative to
that for the untreated healthy rat lungs.

5.2.7. Lung Myeloperoxidase (MPO) activity
The MPO activity was assessed in the lung tissues as an index of neutrophil
accumulation by the method developed by Goldblum et al. (Goldblum, 1985), with inhouse modifications. The minced right lung tissues (50 mg) were homogenized in upto
0.5 ml of 0.02 M EDTA solution in water (pH= 4.7) on ice and centrifuged at 12,000 rpm
for 15 minutes at 4 ºC to separate the pellet from the supernatant. This pellet was resuspended in 0.5 ml of 0.5 % hexadecyltrimethyl ammonium bromide solution in PBS
(pH = 6) and centrifuged (12,000 rpm, 15 min) at 4 °C. In a 96-well plate, 20 µl of the
supernatant was reacted with 180 µl of 0.17 mg/ml O-dianisidine dihydrochloride and
0.0005 % H2O2 solution in PBS. The absorbance increase in 5 min (∆Abs) was measured
at 405 nm using a plate reader (SynergyTM 2), as an indicator of MPO activity. Finally,
the BCA assay was used to normalize the MPO activity with the protein concentration
and the results were expressed as ∆Abs in 5 min per mg protein.

5.2.7. Data description and statistical analyses
The results of the in vivo assessments were expressed as treatment group mean ±
SE (n=3-10). Statistical analyses for group comparison were carried out using Prism® 7
or JMP-Pro® 12 by student t-test or one-way analysis of variance (ANOVA); p<0.05,
0.01 or 0.001 was considered to be statistically significant. Post-hoc analysis for multiple
comparison testing was performed by the Tukey’s method.
5.3. Results
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5.3.1. SalB reversed impaired exercise endurance in established emphysema
Figure 5.3 shows the treadmill exercise endurance of each rat on day 21-22 and
43-44, before and after three weeks pulmonary administration of saline or SalB at 0.1 or
0.2 mg/kg (three times per week) in the rat models of established emphysema induced
with PPE and CSE, compared to that in healthy rats treated with or without pulmonary
administration of SalB at 0.2 mg/kg. Note that the later data with healthy rats were taken
during the studies described in Chapter 3. Untreated healthy rats ran for 47.7±3.2. The
SalB treatment slightly shortened the running time to 41.6±1.6 min, but this reduction
was not significant. In contrast, the exercise endurance was drastically impaired (i.e.,
reduced) to 6.7±1.1 min of the across group running time or by average 86.0 % on day
21-22 following PPE instillation. Note, however, that these reduced pre-dose running
times were comparable between three different treatment groups of rats. While the saline
treatment left the endurance impaired at 5.7±1.6 min, the SalB treatment at 0.1 mg/kg
only moderately improved them to 15.1±3.3 min or by 20.5 % (p<0.01). However, SalB
at 0.2 mg/ml remarkably improved the running times significantly (p<0.01) to 40.1±2.6
min or by 81.5 % suggesting the functional reversal of established emphysema in this
PPE –induced rat model.
Likewise, the repeated CSE injections reduced the exercise endurance on day 2122 to 8.0±0.2 min, of the across group running times or by average 83.3 %. Again, these
pre-dose running times were equally impaired between two different treatment groups of
rats. While the endurance remained unchanged at 9.0±2.0 min by the saline treatment,
SalB at 0.2 mg/kg again improved the endurance time significantly (p<0.01) to 30.7±5.9
or by average 57.2 %. Figure 5.4 shows difference in the exercise endurance (∆
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Endurance) measured on day 20-21 and day 41-42 i.e., before and after three weeks of
pulmonary administration of saline or SalB at 0.1 or 0.2 mg/kg in the PPE and CSE – rat
models of established emphysema. In the PPE –induced emphysema, three weeks
pulmonary administration of SalB at 0.1 or 0.2 mg/kg increased the endurance
significantly by 10 and 31 –fold (p<0.05), respectively, while in the CSE –induced rat
model of established emphysema, SalB at 0.2 mg/kg increased endurance by 18 –fold
(p<0.05), as compared to saline treated rats. These results strongly suggested the reversal
of functional damages of the emphysematous lungs.
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Figure 5.3: Treadmill exercise endurance of each rat measured on day 21-22 and 43-44, respectively,
before (Pre) and after (Post) three weeks of pulmonary administration of saline or SalB at 0.1 or 0.2
mg/kg (three times per week) in rat models of established emphysema induced with PPC and CSE,
compared to that in healthy rats with or without two weeks pulmonary administration of SalB at 0.2
mg/kg (fives times/week). Each treatment group n = 3-10. Horizontal bar represents group mean value.
Changes of the pre– vs. post- dose exercise endurance were either significant (p<0.01 or p<0.001) or
not significant (NS), identified by the student’s t-test comparing with 0. In healthy rats, SalB treatment
did not change the treadmill endurance (NS).
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Figure 5.4: Difference in the exercise endurance (∆ Endurance) measured on day 20-21 and day
41-42 i.e. before (Pre) and after (Post) three weeks of pulmonary administration of saline or SalB at
0.1 or 0.2 mg/kg (three times per week) in rat models of established emphysema induced with PPE
and CSE. Data: mean±SE (n=3-10); *p<0.05, compared to the corresponding rats with established
emphysema treated with saline, by ANOVA followed by Tukey’s multiple comparison test.

89

5.3.2 SalB reversed airspace enlargement and alveolar destruction in established
emphysema
Figure 5.5 shows the representative alveolar airspace images in the rat models of
established emphysema induced with PPE or CSE on day 43-44 following three weeks
pulmonary administration of saline or SalB at 0.2 mg/kg (three times/week), compared to
those in healthy rats treated with or without pulmonary administration of SalB at 0.2
mg/kg. While the alveolar airspace morphology remained unchanged and appeared to be
normal in healthy rats following SalB administration at 0.2 mg/kg (Figure 5.5 A and B),
abnormal airspace enlargement and alveolar destruction were evident in the PPE and CSE
–induced emphysematous rats following saline treatment (Figure 5.5 C and E,
respectively). However, SalB treatment at 0.2 mg/kg appeared to recover this airspace
enlargement and alveolar destruction in these models of established emphysema (Figure
5.5 D and F, respectively).
The MLI values and DI% in different treatment groups of rats are thus shown in
Figure 5.6 and 5.7, respectively, as group measures of airspace enlargement and alveolar
destruction. As predicted from the alveolar airspace images, the SalB treatment alone did
not alter the MLI value in healthy rats (58.5±3.3 and 54.7±2.0 µm with and without SalB
treatment, respectively), as shown in Figure 5.6. In the PPE -induced emphysematous
rats, the MLI value was significantly increased to 97.8±3.2 µm or by 1.8 –fold (p<0.05),
compared to that in healthy rats. However SalB treatment enabled a significant 58.6 %
(p<0.05) recovery of this airspace enlargement, demonstrating an MLI value of
72.5±1.97 µm. Likewise, as in Figure 5.7, the DI% was significantly elevated to 17.3±1.6
% in the PPE –induced emphysematous rats, compared to 4.3±0.4 % seen in healthy rats
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(p<0.05). However, SalB at 0.2 mg/kg again significantly recovered the DI% to 9.4±0.3
% or by 61.0 % (p<0.05), which suggested that the SalB treatment reversed the airspace
enlargement and alveolar destruction in the PPE –induced model of established
emphysema. Figure 5.8 shows correlation plot between MLI and DI% values of each rat
belonging to the three treatment groups. The MLI and DI% values were highly correlated
indicating a close association between these emphysematous abnormalities.
In the CSE -induced model of established emphysema, the MLI value was also
abnormally higher at 84.6±1.7 µm, a significant 1.6 –fold greater value from 54.7±2.0
µm for healthy rats (p<0.05), as shown in Figure 5.6. However, the SalB treatment at 0.2
mg/kg produced a 74.8 % recovery of the airspace enlargement, as demonstrated by the
MLI value of 62.2±3.4 µm (p<0.05).
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A) Healthy rats treated with saline

B) Healthy rats treated with SalB (0.2 mg/kg)

C) PPE -induced rats treated with saline

D) PPE –induced rats treated with SalB (0.2 mg/kg)

E) CSE –induced rats treated with saline

F) CSE –induced rats treated with SalB (0.2 mg/kg)

Figure 5.5: The representative H&E stained micrographs of the alveolar airspaces in the left lung
lobes in rat models of established emphysema induced with PPE or CSE following three weeks
pulmonary administration of saline or SalB (0.2 mg/kg, three times/week), compared to those in
healthy rats with or without two weeks pulmonary administration of SalB (0.2 mg/kg, five
times/week). Magnification = 25X; the scale bars represent 500 μm.
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Figure 5.6: Mean linear intercept (MLI) values of the alveolar airspaces in the rat models of
established emphysema induced with PPE or CSE following three weeks pulmonary
administrations of saline or SalB at 0.2 mg/kg (three times/week), compared to those in healthy
rats treated with saline or SalB (0.2 mg/kg, five times/week). Data: mean±SE (n=4-6) *p<0.05,
compared to healthy saline treated rats; #p<0.05, compared to the corresponding rats models of
established emphsyema treated with saline, by ANOVA and Tukey’s multiple comparison test.
NS: not significant.
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Figure 5.7: Destructive index (DI) measurements obtained from the H&E stained 100X images
of healthy or PPE –induced emphysema rats either treated with saline or SalB. Data: mean±SE
(n=3) *p<0.05, compared to healthy saline control; #p<0.05, compared to PPE –induced saline
treated control, by ANOVA and Tukey’s multiple comparison test.
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= PPE-induced SalB -treated rats and n = PPEinduced saline treated rats.
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5.3.3. Lung tissue expression of protein markers
To examine if the functional and morphological reversal activities of SalB shown
above are associated with the modulations in the cell death and proliferation activities in
the lung, cleaved caspase 3 and PCNA, were chosen as biomarkers of apoptotic cell death
and proliferation, respectively. Figure 5.9 shows the cleaved caspase 3 expression in the
lungs of PPE –induced rats with or without SalB treatment, relative to that of healthy rats.
The saline treatment left the cleaved caspase 3 expression elevated by 13 –fold (p<0.05),
indicating increased lung cell apoptosis and emphysematous damage. However, the SalB
treatment enabled significant suppression by 94.3 % (p<0.05), suggesting the reversal of
the lung’s apoptotic activity. By contrast, as shown in Figure 5.10, the saline treatment
resulted in rather stimulated PCNA expression, but insignificantly by 1.6 –fold. However,
the SalB treatment significantly increased the PCNA expression further in the PPE –
induced animals (p<0.05), resulting in a 2.6 –fold greater level, when compared to that in
healthy rat lungs (p<0.05).
Figures 5.11 show the (A) cytoplasmic and (B) nuclear expressions of pSTAT3 in
the lungs of the PPE –induced rats with or without SalB treatment, in comparison with
the healthy rats. In the PPE –induced emphysematous rats, both the cytoplasmic and
nuclear expression of pSTAT3 appeared to remain lower by 18.4 and 45.0 %,
respectively, yet these reductions did not reach statistical differences. By contrast, the
SalB treatment seemed to restore or stimulate the pSTAT3 levels, but again, these
changes did not reach statistical differences. However, as shown in Figure 5.12, it
became clear that the SalB treatment normalized the lung expression of VEGF from a
significant 35.6 % reduction (p<0.05) seen in the PPE-induced emphysematous rats
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following saline treatment.
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Figure 5.9: Lung tissue (cytosolic) expression of cleaved caspase 3 in the rat model of
established emphysema induced with PPE following three weeks pulmonary administration
of saline or SalB (0.2 mg/kg, three times/week), relative to that in healthy rats. (A)
Representative western blots of cleaved caspase 3 at 17 and 19 kDa and ß-actin at 42 kDa.
(B) Signal band ratios of cleaved caspase 3 to ß-actin relative to that for the healthy rat
lungs. Data represent mean± SE, from n=3-6, *p<0.05, compared to the healthy rats;
#p<0.05, compared to the PPE-induced saline treated rats, by ANOVA and Tukey’s
multiple comparison test.
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Figure 5.10: Lung tissue (cytosolic) expression of proliferating cell nuclear antigen
(PCNA) in the rat model of established emphysema induced with PPE following three
weeks pulmonary administration of saline or SalB (0.2 mg/kg, three times/week), relative to
that in healthy rats. (A) Representative western blots of PCNA at 36 kDa and ß-actin at 42
kDa. (B) Signal band ratios of PCNA to ß-actin relative to that for the healthy rat lungs.
Data represent mean± SE, from n=3-6, *p<0.05, compared to the healthy rats, by ANOVA
and Tukey’s multiple comparison test.
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Figure 5.11: Lung tissue cytosolic and nuclear expression of pSTAT3 in the rat model of
established emphysema induced with PPE following three weeks pulmonary administration
of saline or SalB (0.2 mg/kg, three times/week), relative to that in healthy rats. (A)
Representative western blots of cytosolic pSTAT3 at 75 kDa, ß-actin at 42 kDa and their
signal band ratios of pSTAT3 to ß-actin relative to that for the healthy rat lungs. (B)
Representative western blots of nuclear pSTAT3 at 75 kDa, lamin B1 at 68 kDa and their
signal band ratios of pSTAT3 to lamin B1 relative to that for the healthy rat lungs. Data
represent mean± SE, from n=2-7.
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Figure 5.12: Lung tissue (cytosolic) expression of VEGF in the rat model of established
emphysema induced with PPE following three weeks pulmonary administration of saline or
SalB (0.2 mg/kg, three times/week), relative to that in healthy rats. (A) Representative
western blots of VEGF at 25 kDa and ß-actin at 42 kDa. (B) Signal band ratios of VEGF to
ß-actin relative to that for the healthy rat lungs. Data represent mean± SE, from n=3-6,
*p<0.05, compared to the healthy rats, by ANOVA and Tukey’s multiple comparison test.

101

5.3.4. Lung MPO activity
Because PPE –induced emphysema and its alveolar destruction are associated
with neutrophil infiltration into the lungs (Antunes & Rocco 2011), the MPO activity was
assessed as a biomarker for neutrophilic lung damage. Figure 5.13 shows the MPO
activities measured with ∆Abs in 5 min normalized by the protein content. In the PPE –
induced emphysematous rats (following saline treatment), the lungs MPO activity was
significantly higher by 4 –fold (p<0.05), compared to that of healthy lungs, indicating
elevated neutrophil infiltration as a result of elastastolytic insult. Following SalB
treatment, the MPO activity still remained equally elevated, which suggested lack of
SalB’s effect on neutrophil infiltration.
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Figure 5.13: Lung MPO activity in the rat model of established emphysema induced with
PPE following three weeks pulmonary administration of saline or SalB (0.2 mg/kg three
times/week), compared to that in healthy rats. The MPO activities were described as the 405
nm absorbance change in 5 min (∆Abs5min) normalized with the sample protein content.
Data: mean± SE, from n=5-8, *p<0.05, compared to the healthy rats, by ANOVA and
Tukey’s multiple comparison test. SalB did not change the MPO activity in the PPE –
induced rats.
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5.4. Discussion
In this chapter, PPE and CSE rat models of established emphysema were used to
determine if pulmonary administration of SalB results in the reversal of emphysematous
lung damages. Initiation of SalB treatment following PPE or CSE –induced functional
impairment enabled a more clinically realistic assessment of its application in the
treatment of emphysema. SalB treatment at 0.2 mg/kg enabled recovery of impaired
functional endurance and morphology in PPE and CSE –induced emphysema. This
recovery was associated with normalization of the lung expressions of cell death marker
cleaved caspase 3 and VEGF along with an increase in proliferative marker PCNA. All
the evidence taken together suggests reversal of established emphysema by pulmonary
administration of SalB.

5.4.1. SalB recovered functional impairment in PPE and CSE –induced established
emphysema
Single orotracheal (OT) instillation of 80 U of PPE induces emphysema in rats by
triggering elastolysis and inflammation, resulting in alveolar structural destruction that is
a characteristic of the disease (Inoue, 2010). Due to its faster onset, progressive and
largely irreversible nature, the elastase model is ideal for testing new therapeutic
approaches for reversing emphysematous damage to the lung (Stevenson & Birrell 2011).
In this study, PPE significantly reduced the exercise endurance in rats by 7.2 –fold (47.7
min è 6.7 min, p<0.05), a clinically relevant observation seen in emphysema patients
(Yao et al. 2012). While treatment with SalB at 0.1 mg/kg only marginally improved the
endurance by 20.5 % (6.7 min è 15.1 min, p<0.05), SalB at 0.2 mg/kg recovered this
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impaired endurance by 81.5 % (6.7 min è 40.1 min, p<0.05).
None of the animal models can reproduce all the features of emphysema as it
occurs in humans since the natural history and the comorbidities that are often observed
in humans are absent in animals (Oliveira et al. 2016). Although widely used, the PPE
experimental model has several limitations because the emphysema is induced by
instillation of a single high dose of a protease rather than a continuous low-grade
inflammation believed to be present in chronic cigarette smokers (Flo et al. 2006). To
address some of these limitations, the CSE –induced emphysema model, first described
by Taraseviciene-Stewart and coworkers, was used in addition to PPE for studying
SalB’s emphysema reversal activities (Taraseviciene-Stewart et al. 2007). In this study,
three IP injections of CSE for 3 weeks significantly reduced exercise endurance of the
rats by 6.0 –fold (47.7 min è 8.0 min, p<0.05), thus suggesting functional impairment as
similarly reported by Zhang et al. (Zhang et al. 2013). However, SalB at 0.2 mg/kg
significantly recovered the impaired exercise endurance by 57.2% (8.0 min è 30.7 min,
p<0.05). Thus, SalB substantially reversed the lung’s functional impairment of treadmill
exercise endurance in both PPE and CSE –induced established emphysema.

5.4.2. SalB reversed morphological impairment in PPE and CSE –induced established
emphysema
Single instillation of PPE increased MLI by 1.8 –fold (54.6 µm è 97.8 µm) and
DI by 4.0 –fold (4.3 % è17.3 %) (p<0.05), causing significant airspace enlargement and
destruction. Pulmonary administration of SalB showed recovery of the MLI by 58.6 %
(97.8 µm è 72.5 µm) and DI by 61.0 % (17.3 % è 9.4%) (p<0.05). IP injections of

105

CSE also caused significant airspace enlargement resulting in a 1.5 –fold (54.6 µm è
84.6 µm) (p<0.05) increase in MLI as compared to healthy, which showed recovery upon
administration of SalB (0.2 mg/kg) by 74.8 % (84.6 µm è 62.2 µm) (p<0.05). These
findings suggest reversal of abnormal airspace enlargement and destruction by SalB in
the PPE and CSE –induced emphysema.

5.4.3. SalB normalized the lung tissue expression of cleaved caspase-3 and VEGF but
showed no effect on the MPO activity
Cell apoptosis marker, cleaved caspase 3 expression was substantially increased
in PPE –induced emphysema rat lungs by 13 –fold (p<0.05) compared to healthy,
indicating elevated cell death in the lungs of these rats. On the other hand, cleaved
caspase 3 expression was significantly reduced in PPE –induced SalB treated rats by 94.3
% (p<0.05), suggesting inhibition of induced cell death by SalB. PPE –induced
emphysema rats showed higher lung tissue expression of proliferative biomarker PCNA,
which was not significant as compared to healthy rats. Imai et al. also reported increased
PCNA expression in lung tissues of emphysema patients attributing this to the lung repair
response following the elevated cell death (Imai et al. 2005). Since there is persistent
airspace enlargement and destruction in PPE –induced rats, the substantial increase in cell
death may overwhelm the marginally increased cell proliferation. However, treatment
with SalB further significantly increased the lung tissue expression of PCNA by 2.6 –fold
(p<0.05), thus showing SalB’s ability to induce proliferation. These results are consistent
with the previously demonstrated activities of SalB in elevating lung VEGF expression
(Chapter 3) and stimulating pharmacological repair in lung cells by reducing cell death
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and increasing proliferation (Chapter 4).
Both cytoplasmic and nuclear pSTAT3 expressions appeared to be lower in the
PPE –induced emphysema rats and SalB treatment increased these expressions, but
insignificantly. In contrast, the VEGF expression was significantly reduced in PPE –
induced emphysema rats by 35.6 % (p<0.05), similar to the clinically observed epigenetic
VEGF deficiency in emphysema patients (Yasuo et al. 2011). SalB treatment successfully
recovered the reduced VEGF expression, which is consistent with the original hypothesis.
The 4 –fold (p<0.05) increase in MPO activity (∆Abs: 0.34 è 1.42) in PPE –induced rat
lungs was unaffected by administration of SalB at 0.2 mg/kg (∆Abs: 1.42 è1.27),
implying that SalB’s mechanism of action may not involve direct inhibition of neutrophil
infiltration. To further clarify SalB’s direct target and mechanism of action, in vivo
emphysema studies using inhibitors to the JAK2-STAT3-VEGF signaling pathway may
be important.
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5.5 Conclusions
The emphysema study in rats successfully assessed the potential use of pulmonary
administration of SalB at 0.2 mg/kg to normalize the clinically relevant emphysematous
characteristics of impaired functional endurance, airspace enlargement and destruction in
addition to the pathobiological features of induced cleaved caspase 3 and reduced VEGF
expression. SalB at 0.2 mg/kg showed significant improvements in functional endurance
by 81.5 % and 57.2 %, and airspace morphology by 58.6 % and 74.8 % in differently
induced emphysema by PPE and CSE, respectively (p<0.05). These improvements were
accompanied by normalization of the reduced expression of cleaved caspase 3 and VEGF
along with significantly increased expression of PCNA. These results clearly suggested
that pulmonary administration of SalB at 0.2 mg/kg reversed established emphysema in
vivo. Although pSTAT3 expression in cytoplasm and nucleus appeared to increase with
SalB treatment, further studies are required to clearly demonstrate SalB’s STAT3-VEGFdependent mechanism of action.
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CHAPTER 6
SUMMARY AND GENERAL CONCLUSIONS

In this dissertation, SalB was examined in vitro and in vivo as a novel therapeutic
molecule for pulmonary delivery in the treatment of emphysema. SalB’s anti-oxidation
and anti-elastase activities were first assessed in vitro by the chromogenic ABTS+
radical scavenging assay and the chromogenic HSE substrate hydrolysis assay,
respectively. SalB showed potent anti-oxidation activity (IC50 = 3.7 µM), but was devoid
of the anti-elastase activity. Pulmonary administration of SalB at 0.2 mg/kg in normal
healthy rats over two weeks was shown to increase the lung tissue expression of pSTAT3
and VEGF, while causing no abnormalities in functional treadmill exercise endurance
and airspace morphology.
With this encouraging pSTAT3 and VEGF protein data in rats, the in vitro lung
cell studies were carried out, which spanned 1) the anti-cell death activities; 2) the cell
proliferation stimulatory activities; 3) the cell migration stimulatory activities; and 4) the
promoting activities of trans-endothelial MSC recruitment. Both lung epithelial (A549)
and endothelial (HMVEC-L) cells were used, and JAK2, STAT3 and VEGF-dependence
on these SalB’s activities were explored with respective pharmacologic inhibitors. The
anti-cell death activities were measured with the trypan blue exclusion assay and the
propidium iodide-based flow cytometry assay, and SalB at 25 µM inhibited H2O2 (0.1
mM)-induced A549 cell death by 86.0 % and 59.2 %, respectively. SU5416 (VEGF
receptor antagonist; 20 µM) also induced A549 and HMVEC-L cell death by 3.6 and 3.3-
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fold, respectively, but again, SalB at 25 µM inhibited this induced cell death by 88.4 %
and 47.7 %. In the cell proliferation and cell scratch would closure-based migration
assays, SalB at 25 µM stimulated A549 and HMVEC-L cell proliferation by 1.3 and 1.5fold, and cell migration by 1.5 and 1.7-fold, respectively, as compared to vehicle control.
Notably, pharmacological JAK2, STAT3 and VEGF inhibitions significantly inhibited
the anti-cell death and cell proliferation and migration stimulatory activities of SalB,
which supported the JAK2-STAT3-VEGF –dependent mechanisms. In a transendothelial MSC migration assay, SU5416 (5 µM) reduced MSC migration by 51.7 %,
but SalB at 25 µM restored this impaired migration by 60.0 %.
SalB was then examined for the reversal activities in the rat models of established
emphysema induced with porcine pancreatic elastase (PPE) and cigarette smoke extract
(CSE). In both models, exercise endurance was reduced on day 21 by 86.0 and 83.3 %,
respectively, indicating the development of emphysema. SalB was then administered to
the lung at 0.2 mg/kg, three times weekly for three weeks, which found significant 81.5
and 57.2 % improvement of the impaired endurance, suggesting functionality recovery.
The airspace enlargement of these animals was assessed with the mean linear intercept
(MLI), where PPE and CSE-induced animals (with saline treatment) showed 1.8 and 1.6fold increased MLI values, relative to those in the healthy animals. In contrast, the SalB
treatment at 0.2 mg/kg recovered this MLI values by 58.6 and 74.8 %, respectively. In the
PPE-induced model, alveolar structural destruction was also assessed with the destructive
index (DI%). The model resulted in a 4-fold greater DI% than the health animals, which
was recovered by 61.0 % for emphysematous rats treated with SalB. These results clearly
demonstrated the recovery of impaired functional endurance and abnormal airspace
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morphology as a result of SalB treatment.
PPE instillation increased the lung expression of cleaved caspase-3 by about 13fold and reduced the expression of VEGF by 1.6-fold, suggesting induced cell death and
reduced cell proliferation/migration in the lungs of established emphysema. Pulmonary
treatment of SalB at 0.2 mg/kg significantly normalized both proteins. In contrast, the
lung’s PCNA expression in the lungs appeared to be elevated in the PPE-induced rats, yet
SalB treatment still further significantly increased the PCNA expression by 2.6–fold.
Paradoxically, the pSTAT3 expression in both cytoplasmic and nuclear fractions of the
rat lungs seemed to reduce by 1.2 and 1.8-fold in PPE-induced rats. However, SalB
treatment appeared to still increase lung expression of cytoplasmic and nuclear pSTAT3.
This suggested SalB’s mechanism of STAT3-VEGF recovery. However, further
investigation of the lung expression of upstream factors in the STAT3-VEGF signaling
pathway may be necessary to delineate SalB’s mechanism of action. SalB treatment did
not alter the increased neutrophil recruitment in the lungs as a result of PPE instillation,
indicated by the lung MPO activity assay. Therefore, SalB mediated reversal of
emphysema maybe a result of lung VEGF recovery, but may not involve direct neutrophil
recruitment inhibition.
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APPENDIX 1

WESTERN BLOT ANALYSIS

Western blot analysis was performed to assess protein levels in lung cells and
tissues in Chapter 3 and 5. A549 or HMVEC-L cells were plated in 10 cm dishes (1 x 106
cells/dish) and grown to confluence. Upon confluence, treatments were added in 2% FBS
containing medium for A549 cells and complete medium for HMVEC-L cells.
Subsequently, the cells were washed with ice-cold PBS, scrapped with cell scrapper
(Corning) and cell suspension in 1 ml PBS was collected in the 1.5 ml centrifuge tubes.
After centrifugation at 12000 rpm for 2 min (Eppendorf centrifuge 5415 C), cell pellet
was collected and extracted in 100 µl NP-40 lysis buffer using hand homogenizer (Pro
200; Pro Scientific, Inc.) in ice. NP-40 lysis buffer was freshly prepared from 150 mM
NaCl, (Fisher Scientific), 50 mM Tris pH 8.0 (Bio-Rad Laboratories) and 1% NP-40
(Fisher Scientific) and one tablet of cOmpleteTM protease inhibitor cocktail tablet and
one tablet of PhosSTOP phosphatase inhibitor tablet (Roche diagnostics, Indianapolis,
IN) was dissolved in 10 ml of NP-40 buffer. After 1 min of homogenization, the cell
extract was centrifuged at 12,000 rpm for 2 min. Supernatant was collected and 5 µl
aliquot was used for bicinchoninic acid assay (BCA, Pierce, Rockford, IL) to determine
total protein content. The western blot samples were prepared at a protein concentration
of 1.5 µg/µl in loading buffer and denatured at 100 ˚C for 10 min.
For determining the lung tissue protein expression, 300 mg of right lung tissue
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was homogenized with 1 ml of ice-cold NP-40 lysis buffer with protease and phosphatase
inhibitors using a hand homogenizer. After 1 min of homogenization in ice, the tissue
extract allowed to rest for 15 min, vortexed for 10 seconds and centrifuged at 16,000 g in
4˚C (Aventi JE Centrifuge; Beckman Coulter). The supernatant was collected and 2 µl
aliquot was used for the BCA assay to determine total protein content and the rest was
stored at -70˚C. Western blot samples of 2 µg/µl protein concentration were prepared in
Laemmli sample buffer (Bio-Rad laboratories, Hercules, CA) and ß-mercaptoethanol
(1:20) by denaturing the proteins at 100 ˚C for 10 min.
Approximately 40 µg protein was loaded on each well of the 10 % Mini- Protean
Precast

Gels

(Bio-Rad

Laboratories)

from

the

western

blot

samples

and

tris/glycine/sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)
was carried out at 100 V for about 80 minutes. The proteins from the gel were transferred
on to a nitrocellulose or PVDF membrane at 100 V for about 90 min in ice. The
membranes were washed with tris buffered saline (TBS, prepared in-house, pH 7.5) or
phosphate buffered saline (PBS, prepared in house, pH 7.5) containing 0.1 % Tween 20
for 5 minutes and then subjected to 1 h of blocking in the blocking buffers 5% bovine
serum albumin (BSA) in TBS or non fat dry milk (Kroger) in PBS, as recommended for
each antibody by its suppliers, at room temperature on slow shaker. The nitrocellulose
membranes were then incubated with the primary antibodies to protein of interest
overnight at 4 ˚C on slow shaker. Following day, the membranes were washed with
TBS/PBS and then incubated for 80 min in appropriate secondary antibodies conjugated
with HRP (Bio-Rad Laboratories) on the slow shaker at room temperature. The
membranes washed again with TBS/PBS. Subsequently, membranes were incubated in
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the chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific) for 1 min to
develop luminescence and then exposed to autoradiographic films. The image of the
bands were analyzed by densitometry using Image J. Each protein signal was normalized
with the corresponding ß-actin or lamin B1 signal.
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APPENDIX 2

TREADMILL EXERCISE ENDURANCE TRAINING AND TESTING

All the rats were trained to run on the AccuPacer rodent treadmill (Accuscan Instruments,
Columbus, OH). The training protocol is described below.
Day 1: Place the rat in the treadmill and close the cover. Turn on the electric shock and
watch the rat’s movements for 5 minutes. After 5 minutes, start the treadmill at the speed
of 2.0 m/min and slowly increase the speed by 1.0-m/m increments when rat learns to
avoid the electric shock area. When the speed reaches 5.0 m/min, set the timer to 5
minutes. After 5 minutes, stop the treadmill, and place the rat back into its cage. Repeat
the procedure after 3 hours.
Day 2: Place the rat in the treadmill and close the cover. Turn on the electric shock and
start the treadmill at the speed of 3.0 m/min. Slowly increase the speed by 1.0- m/min
increments when the rat learns to run on the treadmill without touching the shock bar.
When the speed reaches 7.0 m/min, set the timer for 10 minutes. After 10 minutes, stop
the treadmill, and place the rat back into its cage. Repeat the procedure after 3 hours.
Day 3: Repeat the Day 2 procedure. Slowly increase the speed by 1.0 m/min increments
until the speed reaches 10 m/min and set the timer for 10 minutes. After 10 minutes, stop
the treadmill and place the rat back into its cage. Repeat the procedure after 3 hours.
Day 4: Place the rat in the treadmill and close the cover. Turn on the electric shock and
start the treadmill at the speed of 10 m/m. Set the timer for 15 minutes. After 15 minutes,
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stop the treadmill and place the rat back into its cage. Repeat the procedure after 3 hours.
Days 5-10: Place the rat in the treadmill and close the cover. Turn on the electric shock
and start the treadmill at the speed of 10 m/min. Set the timer for 30 minutes. After 30
minutes, stop the treadmill and place the rat back into its cage.

Criteria for a well-trained rat: running on the treadmill without touching the electric
shock for at least 3 minutes. After PPE or CSE induction, training schedule was limited
to Monday, Wednesday, and Friday, twice a day, each time for 5 minutes.

Exercise endurance test:
1.

Turn on the treadmill and the electric foot shock.

2.

Raise the height of the treadmill to a 5 degree angle

3.

Place the rat on the treadmill and start at a speed of 10 m/min. Start the timer

4.

Carefully watch the rat’s running and record how many times it touches the electric foot shock in the
first 2 minutes.

5.

After 2 minutes, record the time of each shock for 5 shocks total.

6.

When the rat runs for over 30 minutes, raise the treadmill angle to 10 degrees

7.

When the rat runs for over 40 minutes, raise the angle to 15 degrees
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APPENDIX 3

COUNTING OF MIGRATED DILC12-LABELED MSCs USING IMAGE J

ImageJ (NIH) software was used to count the MSCs migrated to the basolateral
side of the fluoroblock transwell filters in 24 h. The following procedure was used for
cell counting using ImageJ:
1. Convert the image into 8-bit by going to Image-type- 8-bit

2. Subtract background by going to Process-Subtract background and setting the rolling
ball radius to 12.0 pixels
3. Sharpen the image by going to Process-Sharpen
4. Adjust the threshold by going to Image-Adjust-Threshold. Most common adjustment
for threshold is between 8-15, such that most cells are defined as black dots against white
background. Keep the threshold constant for all the images analyzed.
5. For counting the cells go to Analyze-Particles and setting the parameters to:
Size: 75-1000000
Circularity: 0.1-1.0
Show: Outlines
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6. The image obtained will show the cells counted and the results give the number of
cells.
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Anti-oxidative activity assessment-ABTS radical scavenging assay

Concentration
0
0.01
0.1
0.5
1
2.5
5
7.5
10
25
50
100

n=1
0.186
0.18
0.159
0.198
0.177
0.148
0.058
0.001
0
0
0
0

n=2
0.189
0.192
0.193
0.188
0.19
0.148
0.052
0.001
-0.001
0
0
0.001

n=3
0.198
0.193
0.193
0.192
0.188
0.148
0.045
0
0
-0.001
0
0

Anti-oxidative activity assessment-HSE hydrolysis assay
Concentration
0
0.1
1
10
25
50
100
200

n=1
0.974
0.975
0.975
0.967
0.954
0.95
0.952
0.962

n=2
1.016
1.04
0.98
1.036
0.969
0.967
0.971
1.001

n=3
1.01
0.988
1.043
0.996
1.018
1.009
1.007
0.988

Western blot-pSTAT3 expression in lung tissues
Treatment

Animal

Healthy
Healthy
Healthy
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg

H 15
H5
H10
TR 178
TR 169
TR 177
TR 165
TR 166

pSTAT3/bAverage
SE
actin
0.973
1.00
0.15
1.276
0.751
1.784
1.76
0.20
1.840
2.390
1.627
1.157
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Western blot-VEGF expression in lung tissues
Treatment
Healthy
Healthy
Healthy
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg
SalB 0.2 mg/kg

Animal
H5
H 15
H10
TR 165
TR 166
TR 169
TR 177
TR 178

VEGF/b-actin
Average
SE
0.82
1.00
0.10
1.18
1.00
1.79
1.44
0.13
1.15
1.44
1.68
1.13

% Stained A549 cells- trypan blue exclusion assay-H2O2 –induced cell death
Treatment
Vehicle contol
SalB 25 µM
0.1 mM H2O2
+ 1µM SalB
+ 10µM SalB
+ 25µM SalB

n=1
n=2
n=3
n=4
n=5
n=6
Average SD
0.75
1.09
0.40
2.10
1.53
1.07
1.16
0.597
1.86
1.33
1.59
1.59
0.265
7.59
6.63
7.98
7.27
7.14
8.32
7.49
0.608
6.72
5.58
6.32
6.21
0.578
3.10
1.81
2.60
2.16
2.42
0.558
2.65
1.80
1.19
2.53
2.04
0.681

% Propidium iodide stained A549 cells- Flow cytometry H2O2 –induced cell death
Treatment
Vehicle control
H2O2 0.1 mM
+SalB 25 µM

n=1

n=2

n=3
1.8
9.85
4.63

1.6

10.25
5.72

Average
SD
1.65
1.68
9.79
9.96
4.825
5.06

0.10
0.25
0.58

% Stained A549 cells- trypan blue exclusion assay- SU5416 –induced cell death with
inhibitors
Treatment
SU5416 10 µM
+SalB 25 µM
SU5416 20µM
+SalB 25µM
SU5416 20µM+AG490 25µM
SU5416 20µM+AG490+SalB
25µM
SU5416 20µM+S31-201 100µM
SU 20µM+S31-201+SalB 25µM

n=1

n=2

n=3

3.63
1.29
5.41
2.50
6.03
5.49

3.16
1.52
5.51
1.46
5.57
5.48

Average
SD
2.16
2.98
1.34
1.41
6.09
6.42
2.59
2.18
4.22
5.28
6.92
5.97

5.84
5.21

5.39
6.16

6.23
3.17

5.82
4.85

0.75
0.16
0.560

0.63
0.94
0.83
0.42
1.53
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% Stained HMVEC-L cells- trypan blue exclusion assay- SU5416 –induced cell death
with inhibitors
Treatment
Vehicle control
SalB 25 µM
SU5416 20 µM
+SalB 25 µM
+S31-201 50 µM
+AG490 25 µM

n=1
11.83
6.20
31.80
21.30
33.23
28.54

n=2

n=3
10.47
7.19
27.91
22.61
40.10
35.92

10.28
11.04
35.91
19.95
32.21
26.65

n=4
7.63
8.97

n=5
8.19

Average
9.68
8.35
31.87
21.29
35.18
30.37

SE
0.78
0.95
2.31
1.39
2.48
2.83

A549 cells- MTT assay –Absorbance at 570 nm
Treatment
Vehicle control (0 h)
Vehicle control (24 h)
Vehicle control (48 h)
SalB 10 µM
SalB 25 µM

n=1
n=2
n=3
n=4
n=5
n=6
n=7
Average
0.307
0.279
0.241 0.266
0.273
0.426
0.314
0.492 0.351
0.396
0.665
0.675
0.615 0.661 0.471 0.751 0.574
0.630
0.978
0.627
0.562 1.038
0.801
1.075
0.943
0.888 0.823
0.932

SD
0.027
0.079
0.089
0.241
0.107

A549 cells-MTT assay-Absorbance at 570 nm with inhibitors

Control
SalB 25 µM
AG 490 25 µM
+SalB 25 µM
S31-201 100 µM
+SalB 25 µM
SU5416 5 µM
+SalB 25 µM

n=1
0.806
1.103
0.884
0.893
0.859
0.893
0.744
0.801

n=2
0.672
1.577
0.631
0.820
0.838
0.820
0.627
0.835

n=3
0.798
1.103
0.863
0.746
0.644
0.746
0.860
0.711

n=4

n=5

n=6

n=7

1.007

0.960

1.130

1.191

0.676
0.676

Average
0.759
1.153
0.793
0.784
0.780
0.784
0.744
0.782

SD
0.075
0.274
0.140
0.074
0.119
0.074
0.116
0.064

HMVEC-L –MTT assay- Absorbance at 570 nm
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Treatment
Vehicle control (0 h)
Vehicle control (24 h)
Vehicle control (48 h)
Vehicle control (24 h)
SalB 5 µM
SalB 10 µM
SalB 25 µM
SalB 50 µM

n=1
0.142
0.23
0.398
0.23
0.33
0.363
0.366
0.33

n=2
0.184
0.306
0.34
0.306
0.306
0.342
0.324
0.355

n=3
0.19
0.307
0.348
0.307
0.307
0.31
0.374
0.389

n=4
0.25
0.25

n=5

n=6

n=7

0.25

Average
0.192
0.273
0.362
0.273
0.314
0.338
0.355
0.358

SD
0.026
0.039
0.041
0.044
0.014
0.027
0.027
0.030

HMVEC-L –MTT assay- Absorbance at 570 nm with inhibitors

Treatment

n=1

n=2

n=3

n=4

n=5

n=6

Control

0.242

0.22

0.212

0.182

SalB 25 µM

0.271

0.307

0.297

AG 490 25
µM
+SalB 25
µM
S31-201 100
µM
+SalB 25
µM
SU5416 5
µM
+SalB 25
µM

0.165

0.186

0.156

0.20
6
0.24
5
0.19
5

0.216

0.24

0.236

0.18
1
0.25
5
0.23
5
0.26
2

Average

SD

0.211

0.021

0.281

0.029

0.195

0.015

0.237

0.013

0.171

0.18

0.177

0.176

0.005

0.192

0.201

0.146

0.180

0.030

0.212

0.177

0.155

0.175

0.029

0.2

0.228

0.216

0.215

0.014

0.241
0.231

n=
7
0.1
92
0.2
71

n=8
0.19
8
0.32
3

n=
9
0.2
37
0.3
07

n=1
0
0.2
3
0.2
97

n=1
1
0.2
17

0.232

0.15
6

HMVEC-L –BrdU assay- Absorbance at 450 nm

Treatment
Vehicle control
SalB 10 µM
SalB 25 µM

n=1
0.272
0.249
0.437

n=2
0.269
0.373
0.398

n=3
0.279
0.537
0.398

n=4
0.348
0.377
0.389

Average
0.292
0.384
0.4055

SD
0.038
0.118
0.021
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% A549 cell scratch wound closure
Treatment
Vehicle control
SalB 10 µM
SalB 25µM

n=1
32.45
27.52
49.55

n=2
33.62
34.91
60.41

n=3
49.46
39.01
56.11

n=4
29.47
46.88
48.56

n=5
35.00
52.18
36.50

n=6
19.97
30.53
53.78

n=7
29.37
55.58
40.57

n=8
25.59
46.02

Average
31.87
40.95
48.94

% A549 cell scratch wound closure with inhibitors

Vehicle control
SalB 25µM
S31-201
+SalB 25 µM
AG490
+SalB 25 µM

n=1
36.23
46.68
36.99
37.90
35.51
24.26

n=2
32.92
48.19
37.68
40.50
38.02
32.04

n=3
28.51
47.94
30.44
43.02
36.79
33.50

Average
32.55
47.60
35.04
40.47
36.78
29.93

SD
3.87
0.81
4.00
2.56
1.26
4.97

% A549 cell scratch wound closure with inhibitors

Vehicle control
SalB 25µM
SU5416 5 µM
+SalB 25 µM

n=1
38.80
47.67
37.12
33.81

n=2
38.80
54.20
35.54
40.73

n=3
41.59
45.62
41.17
45.02

n=4
37.12
48.06
33.89
43.61

n=5

n=6

50.02
36.50

32.24

Average
39.08
49.11
36.08
40.79

SD
1.85
3.25
3.07
4.99

% HMVEC-L cell scratch wound closure time study
Hours
0
3
6
12
18

Control
0
13.4
22.18
45.94
65.21

SalB 10 µM
0
21.33
34.04
66.28
92.6
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SD
8.58
10.84
7.93

% HMVEC-L cell scratch wound closure
Treatment
Vehicle
control
SalB 2.5
µM
SalB 5
µM
SalB 10
µM
SalB 25
µM

n=1
n=2
n=3
n=4
n=5
n=6
n=7
n=8
n=9
n=10 Average SD
49.31 39.92 39.71 38.84 49.89 39.48 51.40 35.17 57.36 39.83 44.09
7.25
42.35 42.46 40.90

41.90

0.87

57.50 63.73 63.79

61.67

3.61

66.72 77.10 66.28 48.29 69.03

65.49

10.55

79.74 78.90 79.52 63.60

75.44

7.90

% HMVEC-L cell scratch wound closure with AG490
Treatment
Vehicle
control
SalB 25
µM
AG490 25
µM
+SalB 25
µM

n=1
n=2
n=3
n=4
n=5
n=6
n=7
21.78 18.54 26.79 22.68 22.95 25.82

n=8

32.66 41.14 33.95 32.77 37.77 38.97

n=9

Average SD
23.09
2.96
36.21

3.58

25.09 23.79 20.05 23.08 23.92 26.54 22.49 26.07 22.53 23.73

2.01

24.87 25.87 29.52 25.69 25.75 23.82 29.66 23.24 28.58 26.33

2.38

% HMVEC-L cell scratch wound closure with inhibitors
Treatment
Vehicle control
SalB 25 µM
SU5416 5 µM
+SalB 25 µM
S31-201 50 µM
+SalB 25 µM

n=1
49.31
66.82
41.3
48.5
50.84
45.61

n=2
39.92
63.95
38.2
47.7
40.42
46.33

n=3
39.71
79.70
48.4
50.8
34.42
42.34

n=4
38.84

n=5
49.89

n=6
39.48

Average
42.86
70.16
42.65
49.02
41.89
44.76

SD
5.24
8.39
5.20
1.59
8.31
2.12
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% MSCs migrated in 24 h
No HPMVEC
HPMVEC
FBS 30%

n=1
9.96
12.60
23.76

n=2
10.53
14.38
25.18

n=3
10.61
14.58
26.76

Average
10.37
13.85
25.23

SD
0.36
1.09
1.50

% MSCs migrated in 24 h upon SU5416 pretreatment with SalB
Treatment
Vehicle
control
SalB 25 µM
SU5416 5 µM
+SalB 25 µM

n=1
16.94

n=2
14.42

n=3
16.41

16.85
7.94
14.77

18.50
7.51
12.75

19.84
8.58
11.74

n=4

7.86
11.9

n=5

6.58
12.81

n=6

11.82

Average SD
15.92
1.33
18.40
7.69
12.63

1.50
0.73
1.15
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Pre and post dose exercise of rats

Healthy
SalB (0.2
mg/kg)
PPE (Pre)
PPE
(Post)
PPE+SalB
0.1 mg/kg
(Pre)
PPE+SalB
0.1 mg/kg
(Post)
PPE+SalB
0.2 mg/kg
(Pre)
PPE+SalB
0.2 mg/kg
(Post)
CSE (Pre)
CSE
(Post)
CSE+SalB
0.2 mg/kg
(Pre)
CSE+SalB
0.2 mg/kg
(Post)

48.46 54.84 57.3
41.16 42.59 37.5

Average SD
52.41 51.67 39.23 30.32 38.7 41.25 62.8 47.70
10.03
45.08
41.58
3.17

6.43
8.86

3.35
2.35

2
2

2.28
2.43

6.2

7.4

2.55

6.1
7.68

13.81
10.69

18.39 18.39 8.38
16.67 9.75

8.35

5.68

4.17

8.99

5.66
5.67

4.41
3.86

5.38

2.53

15.05

5.78

8.94

4.34

40.8

42.72 50

38.98 30.18 37.94

40.10

6.48

5.48
5.85

7.066 5.63
8.23 9.33

16.99 3.64
16.3 6.27

7.76
9.20

5.30
4.22

4.89

7.70

6.90

30.71

13.26

19.63 7.55

3.22

3.22

47.73 31.64 24.29 37.28 12.6
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Mean linear intercept values for each rat
Group
Healthy
SalB 0.2
mg/kg
PPE
PPE+SalB
CSE
CSE+SalB

n=1
62.8
63.37

n=2
54.84
59.90

n=3
57.3
52.30

n=4
52.41

n=5
51.67

111.5
79.02
80.49
59.16

93.7
74.99
83.17
61.14

92.75
69.27
86.44
57.75

95.06
70.80
88.35
70.80

95.91
68.51

n=6
48.86

Average
54.65
58.52

SD
4.92
5.66

97.78
72.52
84.61
62.21

7.76
4.41
3.48
5.89

Destructive index measurements for each rat

Healthy
PPE
PPE+SalB

n=1
4.46
20.24
9.97

n=2
5.00
14.72
8.85

n=3
3.49
16.81
9.32

Average
4.32
17.26
9.38

SD
0.76
2.79
0.56

MLI and DI correlation
Healthy
Healthy
Healthy
TR 202
TR 228
TR 230
TR 199
TR 200
TR 201

62.8
54.84
57.3
111.5
95.06
95.91
79.02
74.99
69.27

4.46
5.00
3.49
20.24
14.72
16.81
9.97
8.85
9.32
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Protein expressions in rat lungs
Cleaved caspase3/b-actin relative to
healthy
Healthy
TR 227
1.052
TR 236
0.849
H 22
1.099
PPE PC
TR 228
13.069
TR 231
19.453
TR 230
6.933
PPE SalB TR 226
2.900
TR 229
3.678
TR 232
1.137
TR 199
0.787
TR 200
0.672
TR 201
0.970

PCNA/b-actin relative to healthy
Healthy
TR 227
1.225
TR 236
0.974
H 22
0.801
PPE PC
TR 228
3.063
TR 231
2.130
TR 230
1.125
TR 202
0.058
PPE SalB
TR 226
4.171
TR 229
3.361
TR 232
1.425
TR 199
2.509
TR 200
3.027
TR 201
1.241

Average

SD

SE

1.000

0.133

0.077

13.15

6.26

3.61

1.69

1.27

0.52

Average
1

SD
0.213

SE
0.123

1.59

1.29

0.65

2.62

1.14

0.46
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nuclear pSTAT3/lamin B1 relative to
healthy
Healthy
TR 227
0.912
TR 219
1.008
TR 236
1.080
PPE PC
TR 228
0.642
TR 231
0.176
TR 221
0.580
TR 213
0.665
PPE SalB
TR 226
0.513
TR 229
0.550
TR 232
0.729
TR 218
0.703
TR 225
1.073
TR 221
1.043

Average

SD

SE

1.000

0.084

0.05

0.516

0.229

0.11

0.759

0.220

0.08

cytolasmic pSTAT3/b-actin relative to
healthy
Healthy
TR 227
1.223
TR 236
0.740
TR 222
1.037
PPE PC
TR 228
1.087
TR 231
0.658
TR 230
0.922
TR 213
0.700
TR 202
0.712

Average

SD

SE

1.000

0.243

0.141

0.816

0.183

0.082

PPE SalB

1.152

0.236

0.089

TR 226
TR 229
TR 232
TR 199
TR 200
TR 201
TR 214

1.145
1.396
0.922
1.036
1.479
0.936
0.773
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VEGF/b-actin relative to healthy
Healthy
TR 227
1.05
TR 222
0.85
TR 236
1.10
PPE PC
TR 228
0.68
TR 231
0.68
TR 202
0.59
TR 230
0.62

Average
1.00

SD
0.13

SE
0.08

0.64

0.05

0.02

PPE SalB

0.96

0.35

0.15

TR 226
TR 229
TR 199
TR 200
TR 201

0.86
1.56
0.90
0.83
0.66

MPO activity assay
Healthy
TR 227
H 10
H11
H12
H20

Average
SD
SE

0.343
0.094
0.042

0.355
0.32
0.365
0.206
0.468

PPE
TR 228
TR 230
TR 231
TR 213
TR 216
TR 220
TR 221

1.26
1.25
1.086
1.321
1.795
1.696
1.515
1.418
0.259
0.098

PPE+SalB
TR 226
TR 229
TR 232
TR 199
TR 200
TR 201
TR 214
TR 225

1.208
1.248
1.140
1.387
1.321
1.322
1.308
1.258
1.274
0.072
0.026
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